

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

20 March 1997 (20.03.97)

International application No.

PCT/US96/09788

Applicant's or agent's file reference

15390-1-2PC

International filing date (day/month/year)

06 June 1996 (06.06.96)

Priority date (day/month/year)

07 June 1995 (07.06.95)

Applicant

MALFROY-CAMINE, Bernard

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

06 January 1997 (06.01.97)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Jocelyne REY-MILLET

Telephone No.: (41-22) 730.91.11

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 15390-1-2PC	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US96/09788	International filing date (day/month/year) 06 JUNE 1996	Priority date (day/month/year) 07 JUNE 1995
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant EUKARION, INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 6 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  06 JANUARY 1997	Date of completion of this report  16 SEPTEMBER 1997
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  Ron Schwadron Telephone No. (703) 308-0196

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US96/09788

## I. Basis of the report

1. This report has been drawn on the basis of *(Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):*

- ☒ the international application as originally filed.
- ☒ the description, pages 1-53 , as originally filed.  
pages NONE , filed with the demand.  
pages NONE , filed with the letter of \_\_\_\_\_.  
pages \_\_\_\_\_ , filed with the letter of \_\_\_\_\_.
- ☒ the claims, Nos. 1-23 , as originally filed.  
Nos. NONE , as amended under Article 19.  
Nos. NONE , filed with the demand.  
Nos. NONE , filed with the letter of \_\_\_\_\_.  
Nos. \_\_\_\_\_ , filed with the letter of \_\_\_\_\_.
- ☒ the drawings, sheets/fig 1-7 , as originally filed.  
sheets/fig NONE , filed with the demand.  
sheets/fig NONE , filed with the letter of \_\_\_\_\_.  
sheets/fig \_\_\_\_\_ , filed with the letter of \_\_\_\_\_.

2. The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE .
- ☒ the claims, Nos. NONE .
- ☒ the drawings, sheets/fig NONE .

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the ~~Supplemental Box~~ Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US96/09788

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims <u>1-23</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-23</u>	NO
Industrial Applicability (IA)	Claims <u>1-23</u>	YES
	Claims <u>NONE</u>	NO

**2. CITATIONS AND EXPLANATIONS**

Claims 1-23 lack an inventive step under PCT Article 33(3) as being obvious over Kabanov et al. (pages 33-36) or Kabanov et al. (pages 63-67) in view of Genentech, Inc. and Rodwell et al.

The claims are drawn to lipidized proteins comprising a polypeptide covalently linked to a lipid through a carbohydrate moiety, a method for making said conjugates, compositions containing said lipidized proteins and a method of diagnosis using said proteins. Kabanov et al. teach lipidized proteins (including antibodies) and methods for making said proteins (see entire document, either reference). Kabanov et al. do not teach that the lipidized proteins comprise a polypeptide covalently linked to a lipid through a carbohydrate moiety. Genentech, Inc. teach that an aminolipid (lipoamine) can be used for attaching a lipid to an immunoconjugate (page 13, paragraph three). A routineer would have realized that said method could have also been used to attach said lipid to an oxidized antibody saccharide, because Rodwell et al. teach that amine containing compounds (e.g. lipoamine) can be attached to antibodies by oxidation of antibody saccharides to aldehydes which can react with amine containing compounds (page 2635, first column, second sentence, *Discussion* section). Genentech, Inc. teaches a wide variety of lipids can be used in the invention (page 4, third paragraph), and coupled with his previous teaching of a lipoamine for lipid conjugates, a routineer would have derived the lipoamine compounds of claims 4-6. A routineer would have applied the instant method to any glycoprotein. The antibodies taught by Kabanov et al. consist of mu or gamma heavy chains and is coded for by an immunoglobulin superfamily gene. A routineer would have used the instant method to lipidize monoclonal antibodies. A routineer would have used the instant method to produce lipidized proteins or antibodies. It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed inventions because Kabanov et al. teach lipidized proteins (including antibodies) and methods for making said proteins, Genentech, Inc. teach that an aminolipid (lipoamine) can be used for attaching a lipid to an immunoconjugate and a routineer would have realized that said method could have also been used to attach said lipid to an (Continued on Supplemental Sheet.)

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US96/09788

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 9-19 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the following reasons.

The description does not disclose how to use the instant invention for the *in vivo* treatment of disease in humans. The only use for the instant invention disclosed in the description is the *in vivo* treatment of disease in humans. Applicant has not enabled the breadth of the claimed invention in view of the teachings of the description. The state of the art is such that is unpredictable from the *in vitro* or *in vivo* data disclosed in the description as to whether (and how) the instant invention could be used for the *in vivo* treatment of disease including in humans. The description provides no working examples demonstrating that the instant invention can be used for the treatment of disease. The *in vivo* data presented in the description do not disclose the use of the instant invention for treatment of any disease *in vivo*. With regards to the use of antibodies for *in vivo* use, Waldmann teaches that the therapeutic use of antibody treatment with any particular antibody is unpredictable from *in vitro* and *in vivo* mouse data alone. Waldmann states "Despite this wide ranging interest, the "magic bullet" of antibody therapy that has been the dream of immunotherapists since the time of Paul Ehrlich has proved elusive." (see page 1657, first column, last paragraph). Waldmann states that results from clinical studies in humans using antibody based therapeutics for the treatment of cancer did not fulfill the hopes engendered by animal studies (see page 1660, second column, last paragraph). Waldmann teaches that the effectiveness of rodent monoclonal antibodies is limited because they "have a short survival time in humans and induce an immune response that neutralizes their therapeutic effect" (page 1658, second column, third paragraph). Waldmann teaches that even human antibodies can be immunogenic by virtue of their idiotypic elements (see page 1659, first column, lines 4 and 5). Harris et al. teach that, "There is widespread acceptance that there is little future for the use of rodent mAbs for *in vivo* human therapy" and goes on to list problems encountered upon the use of murine antibodies for human therapy (see page 42, second column, first paragraph). Harris et al. also states that, "However, the residual HAMA response to chimaeric antibodies is mainly anti-idiotypic, therefore repeated dosing is ineffective" (see page 42, third column).

Regarding the use of lipidized peptides, pharmaceutical therapies in the absence of data establishing that said lipidized proteins can be used for the treatment of humans are unpredictable for the following reasons; (1) the lipidized peptide may be inactivated before producing an effect, i.e. such (Continued on Supplemental Sheet.)

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**CLASSIFICATION:**

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(6): A61K 39/395, 39/40, 39/42, 39/44; G01N 33/53, 33/531, 33/532, 33/536, C07K 16/00, 16/46, 19/00; C12P 21/08 and US Cl.: 424/178.1, 179.1, 181.1, 182.1, 183.1; 435/7.1, 972; 436/536; 530/391.1, 391.3, 391.5, 391.7, 391.9, 402

**V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):**

oxidized antibody saccharide, because Rodwell et al. teach that amine containing compounds (e.g. lipoamine) can be attached to antibodies by oxidation of antibody saccharides to aldehydes which can react with amine containing compounds. A routineer would have lipidized antibodies which bind intracellular proteins because the major purpose of the invention is to deliver proteins intracellularly. One of ordinary skill in the art would have been motivated to do the aforementioned because Kabanov et al. teaches lipidized antibodies and Rodwell et al. teaches the advantages of preparing antibody conjugates via oligosaccharide linkage (see abstract). Kabanov et al. teach that lipidized antibodies can be used to target intracellular proteins (see pages 65-67). A routineer would have administered said lipidized antibody in vivo in a pharmaceutical composition. Kabanov et al. teach lipidized antibody against viral protein (see page 65). A routineer would have prepared lipidized antibody against any art known viral protein. Based on the teachings of Kabanov et al., it would have been obvious to a routineer that lipidized antibodies could have been used in any art known assay (eg. immunoassay) that conventional antibodies were used, wherein it was desirable to detect intracellular antigens (eg. viral antigens). Labeled antibodies for use in immunoassays are well known in the art.

----- **NEW CITATIONS** -----

HARRIS et al. Therapeutic antibodies-the coming of age. TIBTECH. February 1993, Vol. 11, pages 42-44, see entire document.

WALDMANN. Monoclonal Antibodies in Diagnosis and Therapy. Science. 21 June 1991, Vol. 252, pages 1657-1662, see entire document.

FAHEY et al. Status of immune-based therapies in HIV infection and AIDS. Clinical Experimental Immunology. 1992, Vol. 88, pages 1-5, see entire document.

**VIII. CERTAIN OBSERVATIONS ON THE APPLICATION (Continued):**

as proteolytic degradation, immunological inactivation or due to an inherently short half-life of the protein; (2) the lipidized peptide may not reach the target area because, i.e. the protein may not be able to cross the mucosa or the protein may be adsorbed by fluids, cells and tissues where the protein has no effect; and (3) other functional properties, known or unknown, may make the lipidized peptide unsuitable for in vivo therapeutic use, i.e. such as adverse side effects prohibitive to the use of such treatment.

With regards to claims that read on a composition of an anti HIV antibodies for the treatment or prophylaxis of disease, the specification has provided no evidence that the instant invention can be used for treatment of HIV infection in humans. Fahey et al. teach that immunotherapeutic approaches for the treatment of HIV infection in vivo in humans have been largely unsuccessful (see Table 1). Fahey et al. clearly establish that it is unpredictable based on in vitro data alone whether an immunotherapeutic agent can be used for the treatment of HIV.

In addition, there is no guidance in the description as to how to determine the dosage of conjugate to use for diagnosis or treatment of any particular disease. Undue experimentation would be required of one skilled in the art to practice the instant invention using the teaching of the specification and the prior art alone.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US96/09788

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 11

Claims 1-8 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the following reasons.

The description is not enabling for the claimed method wherein the characteristics of a protein are modified. There is no disclosure in the description that the binding affinity, avidity or immunogenicity of the antibodies made by the claimed method are modified. Therefore, the description is not enabling for the instant invention.

Claims 14-22 objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claim indefinite for the following reason(s):

Claims 14-22 are indefinite in that they read on compositions, but claim compounds. The claims need to recite additional ingredients (eg. buffer) that would render these claims compositions instead of compounds. Claim 19 is indefinite in the recitation of "prophylaxis" because it is unclear what this encompasses in the context recited in the claim. Claim 20 is indefinite in the recitation of "diagnostic reporter" because it is unclear what this means or encompasses.

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 15390-1-2PC	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/US96/09788	International filing date (day/month/year) 06 JUNE 1996	(Earliest) Priority Date (day/month/year) 07 JUNE 1995
Applicant EUKARION, INC.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ Certain claims were found unsearchable (See Box I).
2. ☐ Unity of invention is lacking (See Box II).
3. ☐ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing
  - ☐ filed with the international application.
  - ☐ furnished by the applicant separately from the international application,
    - ☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
  - ☐ transcribed by this Authority.
4. With regard to the title, ☒ the text is approved as submitted by the applicant.  
☐ the text has been established by this Authority to read as follows:
5. With regard to the abstract,  

9

☒ the text is approved as submitted by the applicant.  
☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is:  
Figure No. \_\_\_\_\_
  - ☐ as suggested by the applicant.
  - ☐ because the applicant failed to suggest a figure.
  - ☐ because this figure better characterizes the invention.☒ None of the figures.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/09788

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/178.1, 179.1, 181.1, 182.1, 183.1; 435/7.1, 972; 436/536; 530/391.1, 391.3, 391.5, 391.7, 391.9, 402

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KABANOV et al. Effective inhibition of viral reproduction by hydrophobised antiviral antibodies. Biomedical Science. January 1990, Vol. 1, No. 1, pages 63-67, see entire document.	1-23
Y	KABANOV et al. Fatty acylation of proteins for translocation across cell membranes. Biomedical Science. January 1990, Vol. 1, No. 1, pages 33-36, see entire document.	1-23
Y	WO 90/10448 A2 (GENENTECH, INC.) 20 September 1990, see entire document.	1-23



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

25 JULY 1996

Date of mailing of the international search report

04 OCT 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RON SCHWADRON

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/09788

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	RODWELL et al. Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations. Proceedings National Academy Science USA. April 1986, Vol. 83, pages 2632-2636, see entire document.	1-23

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/09788

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 39/395, 39/40, 39/42, 39/44; G01N 33/53, 33/531, 33/532, 33/536, C07K 16/00, 16/46, 19/00; C12P 21/08

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/178.1, 179.1, 181.1, 182.1, 183.1; 435/7.1, 972; 436/536; 530/391.1, 391.3, 391.5, 391.7, 391.9, 402

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

MEDLINE, BIOSIS, EMBASE, DERWENT WPI, CHEM AB, APS search terms: author names, lipidized, lipid, antibody, immunoglobulin, conjugate, immunoconjugate, lipoamine, oxidized, oxidizing, glycoprotein, protein, fatty acid

## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty and of the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

**What parts of the international application may be amended ?**

The claims only.

The description and the drawings may only be amended during international preliminary examination under Chapter II.

**When ?** Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

**Where not to file the amendments ?**

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

**How ?** Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

**What documents must/may accompany the amendments ?**

**Letter (Section 205(b)):**

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confounded with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 15390-1-2PC	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US96/09788	International filing date ( <i>day/month/year</i> ) 06 JUNE 1996	Priority date ( <i>day/month/year</i> ) 07 JUNE 1995
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant EUKARION, INC.		

<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>6</u> sheets.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>0</u> sheets.</p> <p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step or industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>
---

Date of submission of the demand  06 JANUARY 1997	Date of completion of this report  16 SEPTEMBER 1997
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer  Ron Schwadrön
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US96/09788

## I. Basis of the report

1. This report has been drawn on the basis of *(Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):*

- ☒ the international application as originally filed.
- ☒ the description, pages 1-53 , as originally filed.  
pages NONE , filed with the demand.  
pages NONE , filed with the letter of \_\_\_\_\_.  
pages \_\_\_\_\_ , filed with the letter of \_\_\_\_\_.
- ☒ the claims, Nos. 1-23 , as originally filed.  
Nos. NONE , as amended under Article 19.  
Nos. NONE , filed with the demand.  
Nos. NONE , filed with the letter of \_\_\_\_\_.  
Nos. \_\_\_\_\_ , filed with the letter of \_\_\_\_\_.
- ☒ the drawings, sheets/~~fig~~ 1-7 , as originally filed.  
sheets/~~fig~~ NONE , filed with the demand.  
sheets/~~fig~~ NONE , filed with the letter of \_\_\_\_\_.  
sheets/~~fig~~ \_\_\_\_\_ , filed with the letter of \_\_\_\_\_.

2. The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE .
- ☒ the claims, Nos. NONE .
- ☒ the drawings, sheets/~~fig~~ NONE .

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the ~~Supplemental Box~~ Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US96/09788

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims <u>1-23</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-23</u>	NO
Industrial Applicability (IA)	Claims <u>1-23</u>	YES
	Claims <u>NONE</u>	NO

**2. CITATIONS AND EXPLANATIONS**

Claims 1-23 lack an inventive step under PCT Article 33(3) as being obvious over Kabanov et al. (pages 33-36) or Kabanov et al. (pages 63-67) in view of Genentech, Inc. and Rodwell et al.

The claims are drawn to lipidized proteins comprising a polypeptide covalently linked to a lipid through a carbohydrate moiety, a method for making said conjugates, compositions containing said lipidized proteins and a method of diagnosis using said proteins. Kabanov et al. teach lipidized proteins (including antibodies) and methods for making said proteins (see entire document, either reference). Kabanov et al. do not teach that the lipidized proteins comprise a polypeptide covalently linked to a lipid through a carbohydrate moiety. Genentech, Inc. teach that an aminolipid (lipoamine) can be used for attaching a lipid to an immunoconjugate (page 13, paragraph three). A routineer would have realized that said method could have also been used to attach said lipid to an oxidized antibody saccharide, because Rodwell et al. teach that amine containing compounds (e.g. lipoamine) can be attached to antibodies by oxidation of antibody saccharides to aldehydes which can react with amine containing compounds (page 2635, first column, second sentence, *Discussion* section). Genentech, Inc. teaches a wide variety of lipids can be used in the invention (page 4, third paragraph), and coupled with his previous teaching of a lipoamine for lipid conjugates, a routineer would have derived the lipoamine compounds of claims 4-6. A routineer would have applied the instant method to any glycoprotein. The antibodies taught by Kabanov et al. consist of mu or gamma heavy chains and is coded for by an immunoglobulin superfamily gene. A routineer would have used the instant method to lipidize monoclonal antibodies. A routineer would have used the instant method to produce lipidized proteins or antibodies. It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed inventions because Kabanov et al. teach lipidized proteins (including antibodies) and methods for making said proteins, Genentech, Inc. teach that an aminolipid (lipoamine) can be used for attaching a lipid to an immunoconjugate and a routineer would have realized that said method could have also been used to attach said lipid to an (Continued on Supplemental Sheet.)

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US96/09788

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 9-19 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the following reasons.

The description does not disclose how to use the instant invention for the *in vivo* treatment of disease in humans. The only use for the instant invention disclosed in the description is the *in vivo* treatment of disease in humans. Applicant has not enabled the breadth of the claimed invention in view of the teachings of the description. The state of the art is such that is unpredictable from the *in vitro* or *in vivo* data disclosed in the description as to whether (and how) the instant invention could be used for the *in vivo* treatment of disease including in humans. The description provides no working examples demonstrating that the instant invention can be used for the treatment of disease. The *in vivo* data presented in the description do not disclose the use of the instant invention for treatment of any disease *in vivo*. With regards to the use of antibodies for *in vivo* use, Waldmann teaches that the therapeutic use of antibody treatment with any particular antibody is unpredictable from *in vitro* and *in vivo* mouse data alone. Waldmann states "Despite this wide ranging interest, the "magic bullet" of antibody therapy that has been the dream of immunotherapists since the time of Paul Ehrlich has proved elusive." (see page 1657, first column, last paragraph). Waldmann states that results from clinical studies in humans using antibody based therapeutics for the treatment of cancer did not fulfill the hopes engendered by animal studies (see page 1660, second column, last paragraph). Waldmann teaches that the effectiveness of rodent monoclonal antibodies is limited because they "have a short survival time in humans and induce an immune response that neutralizes their therapeutic effect" (page 1658, second column, third paragraph). Waldmann teaches that even human antibodies can be immunogenic by virtue of their idiotypic elements (see page 1659, first column, lines 4 and 5). Harris et al. teach that, "There is widespread acceptance that there is little future for the use of rodent mAbs for *in vivo* human therapy" and goes on to list problems encountered upon the use of murine antibodies for human therapy (see page 42, second column, first paragraph). Harris et al. also states that, "However, the residual HAMA response to chimaeric antibodies is mainly anti-idiotypic, therefore repeated dosing is ineffective" (see page 42, third column).

Regarding the use of lipidized peptides, pharmaceutical therapies in the absence of data establishing that said lipidized proteins can be used for the treatment of humans are unpredictable for the following reasons; (1) the lipidized peptide may be inactivated before producing an effect, i.e. such (Continued on Supplemental Sheet.)

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**CLASSIFICATION:**

The International Patent Classification (IPC) and/or the National classification are as listed below:  
IPC(6): A61K 39/395, 39/40, 39/42, 39/44; G01N 33/53, 33/531, 33/532, 33/536, C07K 16/00, 16/46, 19/00; C12P 21/08 and US Cl.: 424/178.1, 179.1, 181.1, 182.1, 183.1; 435/7.1, 972; 436/536; 530/391.1, 391.3, 391.5, 391.7, 391.9, 402

**V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):**

oxidized antibody saccharide, because Rodwell et al. teach that amine containing compounds (e.g. lipoamine) can be attached to antibodies by oxidation of antibody saccharides to aldehydes which can react with amine containing compounds. A routineer would have lipidized antibodies which bind intracellular proteins because the major purpose of the invention is to deliver proteins intracellularly. One of ordinary skill in the art would have been motivated to do the aforementioned because Kabanov et al. teaches lipidized antibodies and Rodwell et al. teaches the advantages of preparing antibody conjugates via oligosaccharide linkage (see abstract). Kabanov et al. teach that lipidized antibodies can be used to target intracellular proteins (see pages 65-67). A routineer would have administered said lipidized antibody in vivo in a pharmaceutical composition. Kabanov et al. teach lipidized antibody against viral protein (see page 65). A routineer would have prepared lipidized antibody against any art known viral protein. Based on the teachings of Kabanov et al., it would have been obvious to a routineer that lipidized antibodies could have been used in any art known assay (eg. immunoassay) that conventional antibodies were used, wherein it was desirable to detect intracellular antigens (eg. viral antigens). Labeled antibodies for use in immunoassays are well known in the art.

**----- NEW CITATIONS -----**

HARRIS et al. Therapeutic antibodies-the coming of age. TIBTECH. February 1993, Vol. 11, pages 42-44, see entire document.

WALDMANN. Monoclonal Antibodies in Diagnosis and Therapy. Science. 21 June 1991, Vol. 252, pages 1657-1662, see entire document.

FAHEY et al. Status of immune-based therapies in HIV infection and AIDS. Clinical Experimental Immunology. 1992, Vol. 88, pages 1-5, see entire document.

**VIII. CERTAIN OBSERVATIONS ON THE APPLICATION (Continued):**

as proteolytic degradation, immunological inactivation or due to an inherently short half-life of the protein; (2) the lipidized peptide may not reach the target area because, i.e. the protein may not be able to cross the mucosa or the protein may be adsorbed by fluids, cells and tissues where the protein has no effect; and (3) other functional properties, known or unknown, may make the lipidized peptide unsuitable for in vivo therapeutic use, i.e. such as adverse side effects prohibitive to the use of such treatment.

With regards to claims that read on a composition of an anti HIV antibodies for the treatment or prophylaxis of disease, the specification has provided no evidence that the instant invention can be used for treatment of HIV infection in humans. Fahey et al. teach that immunotherapeutic approaches for the treatment of HIV infection in vivo in humans have been largely unsuccessful (see Table 1). Fahey et al. clearly establish that it is unpredictable based on in vitro data alone whether an immunotherapeutic agent can be used for the treatment of HIV.

In addition, there is no guidance in the description as to how to determine the dosage of conjugate to use for diagnosis or treatment of any particular disease. Undue experimentation would be required of one skilled in the art to practice the instant invention using the teaching of the specification and the prior art alone.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US96/09788

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 11

Claims 1-8 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the following reasons.

The description is not enabling for the claimed method wherein the characteristics of a protein are modified. There is no disclosure in the description that the binding affinity, avidity or immunogenicity of the antibodies made by the claimed method are modified. Therefore, the description is not enabling for the instant invention.

Claims 14-22 objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claim indefinite for the following reason(s):

Claims 14-22 are indefinite in that they read on compositions, but claim compounds. The claims need to recite additional ingredients (eg. buffer) that would render these claims compositions instead of compounds. Claim 19 is indefinite in the recitation of "prophylaxis" because it is unclear what this encompasses in the context recited in the claim. Claim 20 is indefinite in the recitation of "diagnostic reporter" because it is unclear what this means or encompasses.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/395, 39/40, 39/42, 39/44, G01N 33/53, 33/531, 33/532, 33/536, C07K 16/00, 16/46, 19/00, C12P 21/08</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/40248</b>  <b>(43) International Publication Date:</b> 19 December 1996 (19.12.96)
<b>(21) International Application Number:</b> PCT/US96/09788  <b>(22) International Filing Date:</b> 6 June 1996 (06.06.96)  <b>(30) Priority Data:</b> 08/482,116                      7 June 1995 (07.06.95)                      US  <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US    08/482,116 (CIP) Filed on    7 June 1995 (07.06.95)  <b>(71) Applicant (for all designated States except US):</b> EUKARION, INC. [US/US]; 6F Alfred Circle, Bedford, MA 01730 (US).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> Malfroy-Camine, Bernard [FR/US]; 67 Crosby Street, Arlington, MA 02174 (US).  <b>(74) Agents:</b> DUNN, Tracy, J. et al.; Townsend and Townsend and Crew L.L.P., 8th floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TRANSVACULAR AND INTRACELLULAR DELIVERY OF LIPIDIZED PROTEINS		
<b>(57) Abstract</b>  <p>The invention provides methods for targeting a protein, such as an antibody, to intracellular compartments in an eukaryotic cell, methods for enhancing organ uptake of proteins, pharmaceutical compositions of modified proteins for use in human therapy, and methods for manufacturing modified proteins. The modified proteins of the invention comprise an attached lipid portion, wherein one or more acyl groups are linked to the protein through a carbohydrate side-chain and various covalent linkage chemistries which are provided. Lipidized antibodies of the invention can be used for diagnostic and therapeutic uses.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

08/973576

TRANSVASCULAR AND INTRACELLULAR DELIVERY OF LIPIDIZED PROTEINS

5

## FIELD OF THE INVENTION

The invention provides methods for targeting a protein, such as an antibody, to intracellular compartments in a eukaryotic cell, methods for enhancing organ uptake of proteins, pharmaceutical compositions of modified proteins for use in human therapy, and methods for manufacturing modified proteins. The modified proteins of the invention comprise an attached lipid portion, wherein one or more acyl groups are linked to the protein through a carbohydrate side-chain and various covalent linkage chemistries which are provided.

## BACKGROUND OF THE INVENTION

Many naturally-occurring or modified proteins have been proposed as diagnostic and/or therapeutic agents for use in humans and domestic animals. However, proteins are generally only poorly transported across vascular endothelial membranes, if at all, and usually cannot traverse cellular membranes to gain access to intracellular compartments. Thus, for example, antibodies can be raised against purified intracellular proteins, such as transcription factors, intracellular enzymes, and cytoarchitectural structural proteins, but such antibodies generally are not able to enter intact cells and bind to the intracellular antigen targets unless the cell membrane is disrupted.

The advent of monoclonal antibody technology in the mid 1970's heralded a new age of medicine. For the first time, researchers and clinicians had access to essentially unlimited quantities of uniform antibodies capable of binding to a predetermined antigenic site and having various immunological effector functions. These proteins, known as "monoclonal antibodies" were thought to hold great promise in, e.g., the removal of harmful cells, microbial pathogens, and viruses in vivo. Methods allowing the development of specific monoclonal antibodies having binding specificities directed

against almost any desired antigenic epitope, including antigens which are located in intracellular compartments in intact cells, promised a cornucopia of medicinal "magic bullets".

5                   Unfortunately, the development of appropriate therapeutic products based on monoclonal antibodies, as well as polyclonal antisera, has been severely hampered by a number of drawbacks inherent in the chemical nature of naturally-  
10                   occurring antibodies. First, antibodies are generally not able to efficiently gain access to intracellular locations, as immunoglobulins are not able to traverse the plasma membrane of cells, and are typically only internalized, if at all, as a consequence of inefficient endocytotic mechanisms. Second,  
15                   antibodies do not generally cross vascular membranes (e.g., subendothelial basement membrane), hampering the efficient uptake of antibodies into organs and interstitial spaces. Therefore, therapies for many important diseases could be developed if there were an efficient method to get specific, biologically active immunoglobulin molecules across capillary  
20                   barriers and into intracellular locations. For example, the life cycle of a retrovirus such as HIV involves intracellular replication wherein several viral-encoded polypeptides essential for production of infectious virions from an infected cell could potentially be inhibited or blocked if  
25                   specific monoclonal antibodies reactive with the viral-encoded proteins could readily gain access to the intracellular locations where retroviral replication occurs.

                  Immunoliposomes have been produced as a potential targeted delivery system for delivering various molecules  
30                   contained in the liposome to a targeted cell. Immunoliposomes employ immunoglobulins as targeting agents, wherein an acylated immunoglobulin is anchored in the lipid bilayer of the liposome to target the liposome to particular cell types that have external antigens that are bound by the acylated  
35                   immunoglobulin(s) of the immunoliposomes (Connor and Huang (1985) J. Cell Biol. 101: 582; Huang, L. (1985) Biochemistry 24: 29; Babbitt et al. (1984) Biochemistry 23: 3920; Connor et

al. (1984) Proc. Natl. Acad. Sci. (U.S.A.) 81: 1715; Huang et al. (1983) J. Biol. Chem. 258: 14034; Shen et al. (1982) Biochim. Biophys. Acta 689: 31; Huang et al. (1982) Biochim. Biophys. Acta 716: 140; Huang et al. (1981) J. Immunol.

5 Methods 46: 141; and Huang et al. (1980) J. Biol. Chem. 255: 8015). Immunoliposomes generally contain immunoglobulins which are attached to acyl substituents of a liposome bilayer through a crosslinking agent such as N-hydroxysuccinimide and which thus become anchored in the liposome lipid bilayer.

10 Hence, the crosslinked immunoglobulin is linked to the liposome and serves to target the liposomes to specific cell types bearing a predetermined external antigen by binding to the external cellular antigen. While such methods may serve to target liposomes to particular cell types, immunoliposomes  
15 suffer from several important drawbacks that have limited their application as drug-delivery vehicles, particularly for delivering proteins to intracellular locations.

Attempts have been made at modifying proteins so as to facilitate their transport across capillary barriers and  
20 into cells (EP 0 329 185), however, no completely satisfactory method has yet been reported in the art. Chemical modification of proteins, such as antibodies, by non-specific "cationization" to enhance transvascular and intracellular delivery of proteins, has been reported (U.S.S.N. 07/693,872).  
25 However, present methods for making cationized immunoglobulins lead to a significant loss of binding affinity (approximately about 90 percent) of a cationized immunoglobulin for binding to its predetermined epitope as compared to the comparable non-cationized immunoglobulin. Generally, cationization  
30 involves carbodiimide linkage of a diamine, such as putrescine or hexanediamine, to the carboxylates of aspartate and glutamate residues in the immunoglobulin polypeptide sequence. These chemical modifications of primary amino acids likely  
35 immunoglobulin sufficiently to account for the loss in binding affinity. Also, present methods produce some degree of cationization in glutamate and aspartate residues located in

the variable domain of an immunoglobulin chain, which results in significant loss of binding affinity and/or specificity.

Chemical modification of small molecules has also been proposed as a method to augment transport of small bioactive compounds. Felgner (WO91/17242) discloses forming lipid complexes consisting of lipid vesicles and bioactive substances contained therein. Felgner et al. (WO91/16024) discloses cationic lipid compounds that are allegedly useful for enhancing transfer of small bioactive molecules in plants and animals. Liposomes and polycationic nucleic acids have been suggested as methods to deliver polynucleotides into cells. Liposomes often show a narrow spectrum of cell specificities, and when DNA is coated externally on to them, the DNA is often sensitive to cellular nucleases. Newer polycationic lipospermines compounds exhibit broad cell ranges (Behr et al., (1989) Proc. Natl. Acad. Sci. USA 86:6982) and DNA is coated by these compounds. In addition, a combination of neutral and cationic lipid has been indicated as a method for transfection of animal cells (Rose et al., (1991) BioTechniques 10:520).

Other approaches to enhancing delivery of drugs, particularly across the blood-brain barrier, utilize pharmacologic-based procedures involving drug latentiation or the conversion of hydrophilic drugs into lipid-soluble drugs. The majority of the latentiation approaches involve blocking the hydroxyl, carboxyl and primary amine groups on the drug to make it more lipid-soluble and therefore more easily transported across the blood-brain barrier. Pardridge and Schimmel, U.S. Patent 4,902,505, disclose chimeric peptides for enhancing transport by receptor-mediated transcytosis.

Thus, there exists a need in the art for methods of facilitating transport of specific proteins, such as antibodies, across capillary barriers and into cells, and for pharmaceutical compositions of such immunoglobulins for treating human and veterinary diseases which are amenable to treatment with intracellular proteins and targeting agents like monoclonal antibodies.

## SUMMARY OF THE INVENTION

The prior art method of increasing antibody transport into cells by attaching a cationic substituent to the primary polypeptide sequence of an immunoglobulin by a relatively nonspecific linkage chemistry have been observed to produce detrimental alterations in the secondary, tertiary, and/or quaternary structure of the protein. These structural alterations apparently cause the loss of binding affinity observed in cationized antibodies. To overcome this, the present invention provides methods wherein lipid substituents are linked to a protein, such as an immunoglobulin, typically by covalent linkage to a carbohydrate side chain of the protein such that the lipid substituent does not substantially destroy the biological activity of the protein (e.g., antigen binding).

The invention provides methods for producing lipidized proteins, generally by lipidization of a carbohydrate moiety on a glycoprotein or glycopeptide. In general, the methods of the invention are used for attaching a lipid, such as a lipoamine, to a polypeptide, typically by covalent linkage of the lipid to a carbohydrate moiety on a protein, wherein the carbohydrate moiety generally is chemically oxidized and reacted with a lipoamine to form a lipidized protein. The resultant lipidized protein generally has advantageous pharmacokinetic characteristics, such as an increased capacity to cross vascular barriers and access parenchymal cells of various organs and an increased ability to access intracellular compartments. In one aspect of the invention, lipidization of proteins, such as antibodies directed against transcription factors (e.g., Fos, Jun, AP-1, OCT-1, NF-KB), enhances intranuclear localization of the lipidized protein(s), including for diagnostic detection of antigens in cells, either fixed (e.g., histological sample) or as intact, viable cells, such as cultured cells or cellular explants.

The invention also provides methods for producing lipidized antibodies that are efficiently transported across

capillary barriers and internalized into mammalian cells in vivo. The methods of the invention relate to methods for chemically attaching at least one lipid substituent (e.g., lipoamine) to a carbohydrate substituent on an immunoglobulin to produce a carbohydrate-linked lipidized immunoglobulin, wherein the lipidized immunoglobulin is capable of intracellular localization. In alternate embodiments of the invention, at least one lipid substituent (e.g., lipoamine) is covalently attached to a non-carbohydrate moiety on a protein or polypeptide (e.g., by formation of an amide linkage with a Asp or Glu residue side-chain carboxyl substituent or a thioester linkage with a Cys residue). Also, a fatty acid can be linked to an Arg or Lys residue by the side-chain amine substituents.

Similarly, lipid substituents can be covalently attached to peptidomimetic compounds. Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed "peptide mimetics" or "peptidomimetics" (Fauchere, J. (1986) Adv. Drug Res. 15: 29; Veber and Freidinger (1985) TINS p.392; and Evans et al. (1987) J. Med. Chem 30: 1229, which are incorporated herein by reference) and are usually developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biological or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of:  $-\text{CH}_2\text{NH}-$ ,  $-\text{CH}_2\text{S}-$ ,  $-\text{CH}_2\text{-CH}_2-$ ,  $-\text{CH=CH}-$  (cis and trans),  $-\text{COCH}_2-$ ,  $-\text{CH(OH)CH}_2-$ , and  $-\text{CH}_2\text{SO}-$ , by methods known in the art and further described in the following references: Spatola, A.F. in "Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins," B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983); Spatola, A.F., Vega Data (March

1983), Vol. 1, Issue 3, "Peptide Backbone Modifications" (general review); Morley, J.S., Trends Pharm Sci (1980) pp. 463-468 (general review); Hudson, D. et al., Int J Pept Prot Res (1979) 14:177-185 (-CH<sub>2</sub>NH-, CH<sub>2</sub>CH<sub>2</sub>-); Spatola, A.F. et al., Life Sci (1986) 38:1243-1249 (-CH<sub>2</sub>-S); Hann, M.M., J Chem Soc Perkin Trans I (1982) 307-314 (-CH-CH-, cis and trans); Almquist, R.G. et al., J Med Chem (1980) 23:1392-1398 (-COCH<sub>2</sub>-); Jennings-White, C. et al., Tetrahedron Lett (1982) 23:2533 (-COCH<sub>2</sub>-); Szelke, M. et al., European Appln. EP 45665 (1982) CA: 97:39405 (1982) (-CH(OH)CH<sub>2</sub>-); Holladay, M.W. et al., Tetrahedron Lett (1983) 24:4401-4404 (-C(OH)CH<sub>2</sub>-); and Hruby, V.J., Life Sci (1982) 31:189-199 (-CH<sub>2</sub>-S-); each of which is incorporated herein by reference. A particularly preferred non-peptide linkage is -CH<sub>2</sub>NH-. Such peptide mimetics may have significant advantages over polypeptide embodiments, including, for example: more economical production, greater chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity, and others. Lipidization of peptidomimetics usually involves covalent attachment of one or more acyl chains, directly or through a spacer (e.g., an amide group), to non-interfering position(s) on the peptidomimetic that are predicted by quantitative structure-activity data and/or molecular modeling. Such non-interfering positions generally are positions that do not form direct contacts with the macromolecules(s) (e.g., receptors) to which the peptidomimetic binds to produce the therapeutic effect. Lipidization of peptidomimetics should not substantially interfere with the desired biological or pharmacological activity of the peptidomimetic.

The invention also relates to therapeutic and diagnostic compositions of lipidized proteins, such as lipidized antibodies, that can cross vascular membranes and enter the intracellular compartment, particularly lipidized antibodies that bind to intracellular immunotherapeutic targets, such as viral-encoded gene products that are

essential components of a viral life cycle (e.g., HIV-1 Tat protein), to intracellular antigens that are biologically active (e.g., an oncogene protein such as c-fos, c-src, c-myc, c-lck (p56), c-fyn (p59), and c-abl), and/or to transmembrane or extracellular antigens (e.g., polypeptide hormone receptors such as an IL-2 receptor, PDGF receptor, EGF receptor, NGF receptor, GH receptor, or TNF receptor). Other proteins which can be targeted by lipidized antibodies include, but are not limited to, the following: c-ras p21, c-her-2 protein, c-raf, any of the various G proteins and/or G-protein activating proteins (GAPs), transcription factors such as NF-AT, calcineurin, and cis-trans prolyl isomerases. The lipidized antibodies can be used to localize a diagnostic reagent, such as a radiocontrast agent or magnetic resonance imaging component, to a specific location in the body, such as a specific organ, tissue, body compartment, cell type, neoplasm, or other anatomical structure (e.g., a pathological lesion). The lipidized antibodies can also be used to localize linked therapeutic agents, such as chemotherapy drugs, radiosensitizing agents, radionuclides, antibiotics, and other agents, to specific locations in the body. Alternatively, the lipidized antibodies of the invention can be used therapeutically for neutralizing (i.e., binding to and thereby inactivating) an intracellular target antigen, such as HIV-1 Tat protein, a transmembrane or membrane-associated antigen target (e.g.,  $\gamma$ -glutamyltranspeptidase, c-ras<sup>H</sup> p21, rasGAP) or an extracellular antigen target (i.e.,  $\beta$ -amyloid protein deposits in the brain of an Alzheimer's disease patient). Lipidized antibodies can traverse the blood-brain barrier and react with extracellular antigen targets that are generally inaccessible to immunoglobulins which circulate in the blood or lymphatic system. Lipidized antibodies can also react with intracellular portions on transmembrane proteins, such as cytoplasmic tails of viral envelope glycoproteins or protein kinase domains of protooncogene proteins (c-src, c-abl), and thus inhibit production of infectious enveloped virus or kinase activity, respectively.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows structural formulae representing various lipoamines that can be used in the invention. The righthand column exemplifies branched-chain lipoamines and the  
5 lefthand column exemplifies straight-chain lipoamines.

Figure 2 is a schematic representation of (1) a glycosylated antibody comprising an immunoglobulin tetramer (two light chains associated with two heavy chains), and (2) a  
10 schematic representation of carbohydrate-linked lipidized immunoglobulins of the invention. For example but not limitation, branched-chain lipoamide substituents are shown attached to partially oxidized carbohydrate sidechains of an immunoglobulin tetramer. Such carbohydrate sidechains may be located in the C<sub>H</sub>, V<sub>H</sub>, C<sub>L</sub>, and/or V<sub>L</sub> regions.

15 Figure 3 shows the beneficial effect of a lipidized anti-Tat immunoglobulin on the in vitro survival of cells infected with HIV-1 as compared to the lack of effect of the native (i.e., non-lipidized) anti-Tat immunoglobulin.

Fig. 4 shows that the lipidized anti-Tat antibody  
20 significantly inhibited CAT activity (by approximately 75%), whereas native (unlipidized) anti-Tat antibody, lipidized anti-gp120 antibody, or rSCD4 were far less effective in inhibiting CAT activity in HLCD4-CAT cells.

Fig. 5 shows the effect of lipidized anti-Tat  
25 antibody on CAT expression in HIV-1 LTR-transfected HeLa cells.

Fig. 6A and 6B show the effect of lipidized anti-Tat antibody on HIV-1 replication in living cells.

Fig. 7 shows the effect of lipidized anti-Tat  
30 antibody on HIV-1 replication in living cells.

DETAILED DESCRIPTIONDefinitions

Unless defined otherwise, all technical and  
35 scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar

or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.

5 As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage (Immunology - A Synthesis, 2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Massachusetts (1991), which is incorporated herein by reference).

10 The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide  
15 sequence. In contradistinction, the term "complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is  
20 complementary to a reference sequence "GTATA".

The terms "substantial similarity" or "substantial identity" as used herein denotes a characteristic of a polypeptide sequence or nucleic acid sequence, wherein the polypeptide sequence has at least 50 percent sequence identity  
25 compared to a reference sequence, and the nucleic acid sequence has at least 70 percent sequence identity compared to a reference sequence. The percentage of sequence identity is calculated excluding small deletions or additions which total less than 25 percent of the reference sequence. The reference  
30 sequence may be a subset of a larger sequence, such as a constant region domain of a constant region immunoglobulin gene; however, the reference sequence is at least 18 nucleotides long in the case of polynucleotides, and at least 6 amino residues long in the case of a polypeptide.

35 The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide

sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring. A lipoprotein (e.g., a naturally-occurring isoprenylated or myristylated protein) that can be isolated from an organism that is found in nature and has not been engineered by man is a naturally-occurring lipoprotein.

"Glycosylation sites" refer to amino acid residues which are recognized by a eukaryotic cell as locations for the attachment of sugar residues. The amino acids where carbohydrate, such as oligosaccharide, is attached are typically asparagine (N-linkage), serine (O-linkage), and threonine (O-linkage) residues. The specific site of attachment is typically signaled by a sequence of amino acids, referred to herein as a "glycosylation site sequence". The glycosylation site sequence for N-linked glycosylation is: -Asn-X-Ser- or -Asn-X-Thr-, where X may be any of the conventional amino acids, other than proline. The predominant glycosylation site sequence for O-linked glycosylation is: -(Thr or Ser)-X-X-Pro-, where X is any conventional amino acid. The recognition sequence for glycosaminoglycans (a specific type of sulfated sugar) is -Ser-Gly-X-Gly-, where X is any conventional amino acid. The terms "N-linked" and "O-linked" refer to the chemical group that serves as the attachment site between the sugar molecule and the amino acid residue. N-linked sugars are attached through an amino group; O-linked sugars are attached through a hydroxyl group. However, not all glycosylation site sequences in a protein are necessarily glycosylated; some proteins are secreted in both glycosylated and nonglycosylated forms, while others are fully glycosylated at one glycosylation site sequence but contain another glycosylation site sequence that is not glycosylated. Therefore, not all glycosylation site sequences that are present in a polypeptide are necessarily glycosylation sites where sugar residues are actually attached. The initial N-glycosylation during biosynthesis inserts the "core carbohydrate" or "core oligosaccharide" (Proteins, Structures

and Molecular Principles, (1984) Creighton (ed.), W.H. Freeman and Company, New York, which is incorporated herein by reference).

As used herein, "glycosylating cell" is a cell  
5 capable of glycosylating proteins, particularly eukaryotic cells capable of adding an N-linked "core oligosaccharide" containing at least one mannose residue and/or capable of adding an O-linked sugar, to at least one glycosylation site sequence in at least one polypeptide expressed in said cell,  
10 particularly a secreted protein. Thus, a glycosylating cell contains at least one enzymatic activity that catalyzes the attachment of a sugar residue to a glycosylation site sequence in a protein or polypeptide, and the cell actually glycosylates at least one expressed polypeptide. For example  
15 but not for limitation, mammalian cells are typically glycosylating cells. Other eukaryotic cells, such as insect cells and yeast, may be glycosylating cells.

As used herein, the term "antibody" refers to a protein consisting of one or more polypeptides substantially  
20 encoded by genes of the immunoglobulin superfamily (e.g., see The Immunoglobulin Gene Superfamily, A.F. Williams and A.N. Barclay, in Immunoglobulin Genes, T. Honjo, F.W. Alt, and T.H. Rabbitts, eds., (1989) Academic Press: San Diego, CA, pp.361-387, which is incorporated herein by reference). For example,  
25 but not for limitation, an antibody may comprise part or all of a heavy chain and part or all of a light chain, or may comprise only part or all of a heavy chain. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma (IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, IgG<sub>4</sub>), delta, epsilon and mu constant region  
30 genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin "light chains" (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the NH<sub>2</sub>-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COOH - terminus. Full-length  
35 immunoglobulin "heavy chains" (about 50 Kd or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant

region genes, e.g., gamma (encoding about 330 amino acids). Antibodies include, but are not limited to, the following: immunoglobulin fragments (e.g., Fab, F(ab)<sub>2</sub>, Fv), single chain immunoglobulins, chimeric immunoglobulins, humanized antibodies, primatized antibodies, and various light chain-heavy chain combinations). Antibodies can be produced in glycosylating cells (e.g., human lymphocytes, hybridoma cells, yeast, etc.), in non-glycosylating cells (e.g., in *E. coli*), or synthesized by chemical methods or produced by in vitro translation systems using a polynucleotide template to direct translation.

As used herein, a "lipidized antibody" is an antibody which has been modified by lipid derivatization (e.g., by covalent attachment of a lipoamine, such as glycyldioctadecylamide, dilauroylphosphatidylethanolamine, or dioctadecylamidoglycylspermidine) of one or more carbohydrate moieties attached to an immunoglobulin at a glycosylation site. Generally, the lipid substituent, such as a lipoamine, is covalently attached through a naturally-occurring carbohydrate moiety at a naturally-occurring glycosylation site. However, it is possible to produce immunoglobulins that have altered glycosylation site sequences (typically by site-directed mutagenesis of polynucleotides encoding immunoglobulin chains) and/or altered glycosylation patterns (e.g., by expression of immunoglobulin-encoding polynucleotides in glycosylating cells other than lymphocytes or in lymphocytes of other species). Lipid substituents can be attached to one or more naturally-occurring or non-naturally-occurring carbohydrate moiety on an immunoglobulin chain. When an antibody is produced by direct polypeptide synthesis or by biosynthesis in a non-glycosylating cell (e.g., a phage display library), it will generally be necessary to attach a carbohydrate substituent by chemical or enzymatic modification for subsequent lipidization (alternatively, the carbohydrate may be lipidized prior to attachment to the immunoglobulin). The term "lipidated antibody" may be substituted to "lipidized antibody".

As used herein, a "lipidized protein" refers to a protein (including multimeric proteins, glycoproteins, and polypeptides of various sizes) that has been modified by attachment of lipid (e.g., lipoamine), generally through a carbohydrate moiety. A lipidized protein is generated by derivatizing a protein such that the resultant lipidized protein is distinct from naturally-occurring lipid-linked proteins and lipoproteins. For proteins that are biologically active (e.g., enzymes, receptors, transcription factors), lipidization should not substantially destroy the biological activity (e.g., at least about 15 percent of a native biological activity should be preserved in the lipidized protein). Lipidized peptidomimetics should retain at least about 25 to 95 percent of the pharmacologic activity of a corresponding non-lipidized peptidomimetic.

"Alkyl" refers to a fully saturated aliphatic group which may be cyclic, branched or straightchain. Alkyl groups include those exemplified by methyl, ethyl, cyclopropyl, cyclopropylmethyl, sec-butyl, heptyl, and dodecyl. All of the above can either be unsubstituted or substituted with one or more non-interfering substituents, e.g., halogen;  $C_1$ - $C_4$  alkoxy;  $C_1$ - $C_4$  acyloxy; formyl; alkylenedioxy; benzyloxy; phenyl or benzyl, each optionally substituted with from 1 to 3 substituents selected from halogen,  $C_1$ - $C_4$  alkoxy or  $C_1$ - $C_4$  acyloxy. The term "non-interfering" characterizes the substituents as not adversely affecting any reactions to be performed in accordance with the process of this invention. If more than one alkyl group is present in a given molecule, each may be independently selected from "alkyl" unless otherwise stated.

"Alkylenes" refers to a fully saturated divalent radical containing only carbon and hydrogen, and which may be a branched or straight chain radical. This term is further exemplified by radicals such as methylene, ethylene, n-propylene, t-butylene, i-pentylene, n-heptylene, and the like. All of the above can either be unsubstituted or substituted with one or more non-interfering substituents,

e.g., halogen; C<sub>1</sub>-C<sub>4</sub> alkoxy; C<sub>1</sub>-C<sub>4</sub> acyloxy; formyl; alkylenedioxy; benzyloxy; phenyl or benzyl, each optionally substituted with from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>4</sub> alkoxy or C<sub>1</sub>-C<sub>4</sub> acyloxy. The term "non-interfering" characterizes the substituents as not adversely affecting any reactions to be performed in accordance with the process of this invention. If more than one alkylene group is present in a given molecule, each may be independently selected from "alkylene" unless otherwise stated.

"Aryl", denoted by Ar, includes monocyclic or condensed carbocyclic aromatic groups having from 6 to 20 carbon atoms. Aryl groups include those exemplified by phenyl and naphthyl. These groups may be substituted with one or more non-interfering substituents, e.g., those selected from lower alkyl; lower alkenyl; lower alkynyl; lower alkoxy; lower alkylthio; lower alkylsulfinyl; lower alkylsulfonyl, dialkylamine; halogen; hydroxy; phenyl; phenyloxy; benzyl; benzoyl; and nitro. Each substituent may be optionally substituted with additional non-interfering substituents.

"Amino" refers to the group -NH<sub>2</sub>.

"Alkylcarbonyl" refers to the group -(CHR<sub>1</sub>)-CO- wherein R<sub>1</sub> is further designated the  $\alpha$ -position. R<sub>1</sub> may be hydrogen, alkyl, or an amino group. Preferably R<sub>1</sub> is an amino group.

#### Description of the Preferred Embodiments

In accordance with the present invention, novel methods for chemically modifying proteins, such as antibodies, to facilitate passage across capillary barriers and into cells are provided. In general, the methods include the covalent attachment of at least one non-interfering lipid substituent (e.g., glycyldioctadecylamide, glycyldiheptadecylamide, glycyldihexadecylamide, dilauroylphosphatidylethanolamine, and glycyldioctadecadienoylamide) to a reactive site in the protein molecule (e.g., a periodate-oxidized carbohydrate moiety). Various non-interfering lipid substituents may be attached to proteins to produce lipidized proteins, such as

lipidized antibodies of the invention. For example but not for limitation, the following examples of lipids may be conjugated to a protein of interest to yield a lipidized protein: lipoamines, lipopolyamines, and fatty acids (e.g., stearic acid, oleic acid, and others). Generally, the lipid will be attached by a covalent linkage to a carbohydrate linked to the protein (e.g., a carbohydrate side chain of a glycoprotein). Naturally-occurring carbohydrate side-chains are preferably used for linkage to a lipoamine, although novel glycosylation sites may be engineered into a polypeptide by genetic manipulation of an encoding polynucleotide, and expression of the encoding polynucleotide in a glycosylating cell to produce a glycosylated polypeptide.

Glycosylated proteins can be lipidized to enhance transvascular transport, organ uptake, and intracellular localization of the lipidized protein, including intranuclear localization. Generally, a glycosylated polypeptide, such as an antibody, is chemically oxidized with an oxidizing agent (e.g., periodate) to yield pendant carboxyl and/or aldehyde groups, and reacted with a lipoamine to form a covalent (amide or imide, respectively) bond linking the lipoamine to the protein. Typically, the oxidation of the carbohydrate side-chain is a partial oxidation producing at least one reactive carboxyl or aldehyde group, although generally chemical oxidation methods will produce some molecules that are partially oxidized and others that are either unoxidized or completely oxidized. However, in order to be lipidized by reaction with a lipoamine, the glycoprotein must be oxidized to produce at least one pendant aldehyde group that can react with a lipoamine, although it may be possible to produce lipidized proteins through linkage to pendant carboxyl groups as well. A pendant carboxyl or aldehyde group of an oxidized glycoprotein is a carboxyl or aldehyde group having a carbonyl carbon derived from an oxidized oligosaccharide and which is covalently attached to the protein, either directly or through a spacer (e.g., an unoxidized portion of a N- or O-linked carbohydrate side-chain). Preferably, N-linked and O-linked

carbohydrate chains are incompletely oxidized to generate a multiplicity of reactive aldehyde and carboxyl groups at each glycosylation position for subsequent reaction with lipoamines. Most usually, glycoproteins having one or more complex N-linked oligosaccharides, such as those having a branched (mannose)<sub>3</sub>(β-N-acetylglucosamino) core, are partially oxidized by limited reaction with a suitable oxidant, generally periodate. Linked oligosaccharides containing N-acetylglucosamine (NAG), mannose, galactose, fucose (6-deoxygalactose), N-acetylneuraminic acid (sialic acid), glucose, N-acetylmuramic acid, N-acetylgalactosamine, xylose, or combinations of these monosaccharide units can be oxidized and reacted with lipoamines to produce lipidized proteins, more specifically carbohydrate-linked lipidized proteins. Glycoproteins containing linked oligosaccharides with monosaccharide units other than those specifically listed above for exemplification, including non-naturally occurring monosaccharides, can also be oxidized and covalently linked to a lipoamine to form a lipidized protein.

Lipoamines are molecules having at least one acyl group and at least one free amine (i.e., a primary or secondary amine). It is believed that the invention can also be practiced with lipoamines that have tertiary amines which comprise at least one substituent that can be displaced by reaction with an oxidized carbohydrate. Examples of lipoamines having a primary amine are shown in Fig. 1. For example, the invention can produce lipidized proteins by reacting a glycoprotein with a straight-chain lipoamine of the formula:



where R is: a disubstituted alkyl (alkylene), preferably methylene (-CH<sub>2</sub>-); a 1,4-disubstituted cyclohexyl; a disubstituted aryl (arylene); preferably a 1,4-disubstituted phenyl (phenylene); an amido group of the formula -(CHR<sub>1</sub>)-CO-NH- wherein R<sub>1</sub> is hydrogen or an amino group; alkylcarbonyl,

preferably  $\alpha$ -amino substituted alkylcarbonyl; or a phosphate diester, preferably of the formula  $-\text{CH}_2-\text{O}-\text{PO}_2-\text{O}-$ .  $n$  is an integer which is typically 1 to 50, preferably about 5 to 30, more preferably about 10 to 25, and most usually about 15 to 20. In general,  $n$  is selected at the discretion of the practitioner according to the following guideline: when the molecule to be lipidized is large (i.e., a protein of more than about 10 kD) it is preferred that  $n$  is at least about 8 to 12 or more to increase the hydrophobicity of the resulting lipidized protein; when the molecule to be lipidized is small (e.g., an oligopeptide)  $n$  can typically be in the range 2 to 18, but may be larger if additional hydrophobicity of the lipidized molecule is desired.

The invention can also be practiced with branched-chain lipoamines, which, for example, can include lipoamines of the formula:



where  $\text{R}'$  is: a trisubstituted alkyl, preferably  $-\text{CH}_2-\text{CH}<$  or 1,2,4-trisubstituted cyclohexyl; a trisubstituted aryl, preferably 1,2,4-trisubstituted phenyl; an amido group of the formula  $-(\text{CHR}_1)-\text{CO}-\text{N}<$  wherein  $\text{R}_1$  is hydrogen or an amino group; an imino group of the formula  $-\text{CHR}_2-\text{NH}-\text{CH}<$  wherein  $\text{R}_2$  is hydrogen or an amino group or an imino group of the formula  $-\text{CH}_2-\text{N}<$ ; or a phosphate diester, preferably of the formula  $-\text{CH}_2-\text{CH}_2-\text{O}-\text{PO}_2-\text{O}-\text{CH}_2-\text{CH}(\text{CO}_2-)_2$ .  $m$  and  $n$  are selected independently and are integers which are typically 1 to 50, preferably about 5 to 30, more preferably about 10 to 25, and most usually about 15 to 20. In general,  $n$  is selected at the discretion of the practitioner according to the following guideline: when the molecule to be lipidized is large (i.e., a protein of more than about 10 kD) it is preferred that  $m$  and/or  $n$  is at least about 8 to 12 or more to increase the hydrophobicity of the resulting lipidized protein; when the molecule to be lipidized is small (e.g., an oligopeptide)  $n$  can typically be in the

range 2 to 18, but may be larger if additional hydrophobicity of the lipidized molecule is desired.

Essentially any glycoprotein can be lipidized according to the methods of the invention by reacting a lipoamine with an oxidized carbohydrate side-chain. Fig. 2 shows schematically a glycosylated antibody and a carbohydrate-linked lipidized antibody of the invention, respectively. Non-glycosylated proteins may be conjugated to a lipid by linkage through a suitable crosslinking agent (e.g., by carbodiimide linkage chemistry).

In accordance with the present invention, novel lipidized antibodies capable of specifically binding to predetermined intracellular epitopes with strong affinity are provided. These antibodies readily enter the intracellular compartment and have binding affinities of at least about  $1 \times 10^6 \text{ M}^{-1}$ , preferably  $1 \times 10^7 \text{ M}^{-1}$  to  $1 \times 10^8 \text{ M}^{-1}$ , more preferably at least about  $1 \times 10^9 \text{ M}^{-1}$  or stronger. The lipidized antibodies typically have a lipid substituent attached to a naturally-occurring carbohydrate side chain on a donor immunoglobulin chain, which composes an antibody specifically reactive with an intracellular, transmembrane, or extracellular epitope. Since carbohydrates are located on the Fc portion of immunoglobulins, chemical modification of the carbohydrate residues by lipidization would be unlikely to produce a substantial loss of affinity of the antibodies for their antigens (Rodwell et al. (1986) Proc. Natl. Acad. Sci. (U.S.A.) 83: 2632). The lipidized antibodies generally retain substantial affinity for their antigen, and the avidity can be readily measured by any of several antibody-antigen binding assays known in the art. The antibodies can be produced economically in large quantities and find use, for example, in the treatment of various human disorders by a variety of techniques.

One form of immunoglobulin constitutes the basic structural unit of an antibody. This form is a tetramer and consists of two identical pairs of immunoglobulin chains, each pair having one light and one heavy chain. In each pair, the

light and heavy chain variable regions are together responsible for binding to an antigen, and the constant regions are responsible for the antibody effector functions. In addition to antibodies, immunoglobulins may exist in a variety of other forms including, for example, Fv, Fab, and (Fab')<sub>2</sub>, as well as bifunctional hybrid antibodies, fusion proteins (e.g., bacteriophage display libraries), and other forms (e.g., Lanzavecchia et al., Eur. J. Immunol. **17**, 105 (1987)) and in single chains (e.g., Huston et al., Proc. Natl. Acad. Sci. U.S.A., **85**, 5879-5883 (1988) and Bird et al., Science, **242**, 423-426 (1988)). (See, generally, Hood et al., "Immunology", Benjamin, N.Y., 2nd ed. (1984), and Hunkapiller and Hood, Nature, **323**, 15-16 (1986)).

Antibodies can be produced in glycosylating cells (e.g., human lymphocytes, hybridoma cells, yeast, etc.), in non-glycosylating cells (e.g., in *E. coli*), or synthesized by chemical methods or produced by in vitro translation systems using a polynucleotide template to direct translation. One source of hybridoma cell lines and immunoglobulin-encoding polynucleotides is American Type Culture Collection, Rockville, MD. Methods for expression of heterologous proteins in recombinant hosts, chemical synthesis of polypeptides, and in vitro translation are well known in the art and are described further in Maniatis et al., Molecular Cloning: A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y.; Berger and Kimmel, Methods in Enzymology, Volume 152, Guide to Molecular Cloning Techniques (1987), Academic Press, Inc., San Diego, CA; Merrifield, J. (1969) J. Am. Chem. Soc. **91**: 501; Chaiken I.M. (1981) CRC Crit. Rev. Biochem. **11**: 255; Kaiser et al. (1989) Science **243**: 187; Merrifield, B. (1986) Science **232**: 342; Kent, S.B.H. (1988) Ann. Rev. Biochem. **57**: 957; and Offord, R.E. (1980) Semisynthetic Proteins, Wiley Publishing, which are incorporated herein by reference). Antibodies that are produced in non-glycosylating cells can be conjugated to a lipid by use of a bifunctional crosslinking agent or preferably post-translationally glycosylated in a glycosylation system such as purified canine

pancreatic microsomes (Mueckler and Lodish (1986) Cell 44: 629 and Walter, P. (1983) Meth. Enzymol. 96: 84, which are incorporated herein by reference). Alternatively, polynucleotides that encode antibodies may be isolated from screened prokaryotic expression libraries, such as combinatorial antibody fragment display libraries, and subsequently expressed in glycosylating cells to produce glycosylated antibodies. According to these methods, glycosylated antibodies may be obtained, having naturally-occurring and/or non-naturally-occurring glycosylation patterns. Such glycosylated antibodies can be lipidized according to the methods of the invention.

Glycosylation of immunoglobulins has been shown to have significant effects on their effector functions, structural stability, and rate of secretion from antibody-producing cells (Leatherbarrow et al., Mol. Immunol. 22: 407 (1985)). The carbohydrate groups responsible for these properties are generally attached to the constant (C) regions of the antibodies. For example, glycosylation of IgG at asparagine 297 in the C<sub>H</sub>2 domain is required for full capacity of IgG to activate the classical pathway of complement-dependent cytotoxicity (Tao and Morrison, J. Immunol. 143: 2595 (1989)). Glycosylation of IgM at asparagine 402 in the C<sub>H</sub>3 domain is necessary for proper assembly and cytolytic activity of the antibody (Muraoka and Shulman, J. Immunol. 142: 695 (1989)). Removal of glycosylation sites at positions 162 and 419 in the C<sub>H</sub>1 and C<sub>H</sub>3 domains of an IgA antibody lead to intracellular degradation and at least 90% inhibition of secretion (Taylor and Wall, Mol. Cell. Biol. 8: 4197 (1988)).

Glycosylation of immunoglobulins in the variable (V) region has also been observed. Sox and Hood, Proc. Natl. Acad. Sci. USA 66: 975 (1970), reported that about 20% of human antibodies are glycosylated in the V region. Glycosylation of the V domain is believed to arise from fortuitous occurrences of the N-linked glycosylation signal Asn-Xaa-Ser/Thr in the V region sequence and has not been recognized in the art as playing an important role in

immunoglobulin function.

Therefore, it is generally preferred that lipidization is performed on antibodies having naturally-occurring glycosylation patterns. If glycosylation sites are engineered into an antibody, it is preferred that novel glycosylation site be introduced in a constant region or variable region framework region, which are less likely to adversely affect the antigen binding activity of the antibody. It is generally most preferred that novel glycosylation sites which are engineered into an antibody are placed in a constant region.

Alternatively, polypeptide fragments comprising only a portion of a primary antibody structure and having a carbohydrate side chain that may be derivatized with a lipid substituent (e.g., lipoamine) can be produced, which fragments possess one or more immunoglobulin activities (e.g., antigen binding activity). These polypeptide fragments may be produced by proteolytic cleavage of intact antibodies by methods well known in the art, or by site-directed mutagenesis at the desired locations in expression vectors containing sequences encoding immunoglobulin proteins, such as after CH<sub>1</sub> to produce Fab fragments or after the hinge region to produce (Fab')<sub>2</sub> fragments. Single chain antibodies may be produced by joining V<sub>L</sub> and V<sub>H</sub> with a DNA linker (see, Huston et al., op. cit., and Bird et al., op. cit.). Also because like many genes, the immunoglobulin-related genes contain separate functional regions, each having one or more distinct biological activities, the genes may be fused to functional regions from other genes having novel properties. Nucleic acid sequences for producing immunoglobulins for the present invention are capable of ultimately expressing the desired antibodies and can be formed from a variety of different polynucleotides (genomic or cDNA, RNA, synthetic oligonucleotides, etc.) and components (e.g., V, J, D, and C regions), as well as by a variety of different techniques. Joining appropriate synthetic and genomic sequences is presently the most common method of production, but cDNA

sequences may also be utilized (see, European Patent Publication No. 0239400 and L. Reichmann et al., Nature, 332, 323-327 (1988)).

Immunoglobulins and/or DNA sequences encoding  
5 immunoglobulin chains may be obtained, for example, by hybridoma clones which can be produced according to methods known in the art (Kohler and Milstein (1976) Eur. J. Immunol. 6: 511, incorporated herein by reference) or can be obtained from several sources ("ATCC Catalog of Cell Lines and  
10 Hybridomas", American Type Culture Collection, Rockville, MD, which is incorporated herein by reference). DNA sequences encoding immunoglobulin chains can be obtained by conventional cloning methods known in the art and described in various publications, for example, Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989), Cold Spring Harbor, N.Y.  
15 and Berger and Kimmel, Methods in Enzymology, Volume 152, Guide to Molecular Cloning Techniques (1987), Academic Press, Inc., San Diego, CA, which are incorporated herein by reference.

20 As stated previously, the DNA sequences will be expressed in hosts, typically glycosylating cells, after the sequences have been operably linked to (i.e., positioned to ensure the functioning of) an expression control sequence. These expression vectors are typically replicable in the host  
25 organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline-resistance or G418-resistance, to permit detection of those cells transformed with the desired DNA sequences (see, e.g., U.S.  
30 Patent 4,704,362).

*E. coli* is one prokaryotic host useful particularly for cloning the DNA sequences of the present invention. Other microbial hosts suitable for use include bacilli, such as *Bacillus subtilis*, and other Enterobacteriaceae, such as  
35 *Salmonella*, *Serratia*, and various *Pseudomonas* species. In these prokaryotic hosts, one can also make expression vectors, which will typically contain expression control sequences

compatible with the host cell (e.g., an origin of replication). In addition, any number of a variety of well-known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a  $\beta$ -galactosidase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation. Proteins, such as antibodies, that are expressed in non-glycosylating cells can be post-translationally glycosylated in a glycosylation system (Mueckler and Lodish, op.cit., which is incorporated herein by reference.

Other microbes, such as yeast, may also be used for expression. *Saccharomyces* is a preferred host glycosylating cell, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.

In addition to microorganisms, mammalian tissue cell culture may also be used to express and produce the polypeptides of the present invention (see, Winnacker, "From Genes to Clones," VCH Publishers, N.Y., N.Y. (1987)). Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, preferably myeloma cell lines, etc, and transformed B-cells or hybridomas. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen et al., Immunol. Rev., 89, 49-68 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, Adenovirus, cytomegalovirus, Bovine Papilloma Virus, and the like.

The vectors containing the DNA segments of interest

(e.g., the heavy and light chain encoding sequences and expression control sequences) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts. (See, generally, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, (1982).)

Once expressed, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the present invention, can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, "Protein Purification", Springer-Verlag, N.Y. (1982)). Substantially pure immunoglobulins of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically (including extracorporeally) or in developing and performing assay procedures, immunofluorescent stainings, and the like. (See, generally, Immunological Methods, Vols. I and II, Lefkovits and Pernis, eds., Academic Press, New York, N.Y. (1979 and 1981)).

In the methods of the invention, intact immunoglobulins or their binding fragments, such as Fab, are preferably used. Typically, lipidized antibodies will be of the human IgM or IgG isotypes, but other mammalian constant regions may be utilized as desired. Lipidized antibodies of the IgA, IgG, IgM, IgE, IgD classes may be produced. Preferably, the lipidized antibodies of the invention are human, murine, bovine, equine, porcine, or non-human primate antibodies, more preferably human or murine antibodies. The invention can be used to produce lipidized antibodies of various types, including but not limited to: chimeric antibodies, humanized antibodies, primatized antibodies, F<sub>v</sub>

fragments, toxin-antibody conjugates, isotope-antibody conjugates, and imaging agent-antibody conjugates. For in vivo imaging, lipidized antibodies are suitably labeled with a diagnostic label, administered to the patient, and their location determined at various times following administration. Various methods of labeling antibodies with diagnostic reporters (e.g., with  $Tc^{99}$ , other radioligands, radiocontrast agents or radio-opaque dye) are known in the art.

Proteins and oligopeptides (i.e., polypeptides comprising from 2 to about 50 amino acid residues attached in peptidyl linkage) other than immunoglobulins can be lipidized according to the methods the invention. Naturally-occurring glycoproteins (e.g.,  $\gamma$ -glutamyltranspeptidase, thrombomodulin, glucose transporter proteins) are preferred substrates for lipidization through carbohydrate linkage, although substantially any polypeptide can be lipidized by covalent attachment through a crosslinking agent (e.g., N-hydroxysuccinimide) to a suitable amino acid side chain. In alternate embodiments of the invention, at least one lipid substituent (e.g., lipoamine) is covalently attached to a non-carbohydrate moiety on a protein or polypeptide (e.g., by formation of an amide linkage with a Asp or Glu residue side-chain carboxyl substituent or a thioester linkage with a Cys residue). Also, a fatty acid can be linked to an Arg or Lys residue by the side-chain amine substituents. Examples of non-glycosylated proteins which may be lipidized for enhancing transvascular and intracellular transport include, but are not limited to, the following proteins: c-fos, c-myc, c-src, NF-AT, and HMG CoA reductase. Naturally-occurring lipoproteins, such as native proteins which undergo physiological farnesylation, geranylgeranylation, and palmitylation are natural products and are not defined herein as "lipidized proteins".

The lipidized antibodies and pharmaceutical compositions thereof are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly or intravenously. The compositions for parenteral administration

will commonly comprise a solution of the immunoglobulin or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, human albumin, etc. The concentration of antibody in these formulations can vary widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

Thus, a typical pharmaceutical composition for injection could be made up to contain 1 ml sterile buffered water, and 1-10 mgs of lipidized immunoglobulin. A typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of antibody. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania (1980), which is incorporated herein by reference.

The lipidized proteins and antibodies of this invention can be frozen or lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilization and recon-

stitution can lead to varying degrees of activity loss (e.g., with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate.

5           The compositions containing the present lipidized proteins (e.g., antibodies) or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. In therapeutic application, compositions are administered to a patient in an amount sufficient to cure or at least partially  
10       arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the infection and the general state of the patient's own immune system, but generally range from about 1  
15       to about 200 mg of antibody per dose, with dosages of from 5 to 25 mg being more commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is life-threatening or potentially life-threatening situations.

20           In prophylactic applications, compositions containing the present immunoglobulins or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance. Such an amount is defined to be a "prophylactically effective dose." In this  
25       use, the precise amounts again depend upon the patient's state of health and general level of immunity, but generally range from 0.1 to 25 mg per dose.

          Single or multiple administrations of the compositions can be carried out with dose levels and pattern  
30       being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the lipidized proteins and/or lipidized antibody(ies) of this invention sufficient to effectively treat the patient.

          For diagnostic purposes, the lipidized antibodies  
35       may either be labeled or unlabeled. Unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with the lipidized antibody,

such as antibodies specific for human immunoglobulin constant regions. Alternatively, the lipidized antibodies can be directly labeled. A wide variety of labels may be employed, such as radionuclides, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (particularly haptens), radiocontrast agents, metal chelates, etc. Numerous types of diagnostic imaging applications are available and are well known to those skilled in the art. For example, but not for limitation, an antibody that binds to a tumor antigen (e.g., anti-CEA antibodies) may be lipidized and conjugated to a radiocontrast agent or magnetic imaging material, injected into a human patient, and detected so as to localize the position of a tumor or metastatic lesion.

The lipidized immunoglobulins of the present invention can be used for diagnosis and therapy. By way of illustration and not limitation, they can be used to treat cancer, autoimmune diseases, or viral infections. For treatment of cancer, the antibodies will typically bind to an antigen expressed preferentially in certain cancer cells, such as c-myc gene product and others well known to those skilled in the art. Preferably, the lipidized antibody will bind to a mutant protein, such as a c-ras oncogene product having a pathogenic (e.g., neoplastic) sequence, such as a substitution at position 12, 13, 59, or 61 of the protein (e.g., a Ser at position 12 of p21<sup>ras</sup>). For treatment of autoimmune disease, the antibodies will typically bind to an critical regulatory protein expressed primarily in activated T-cells, such as NF-AT, and many other intracellular proteins well known to those skilled in the art (e.g., see Fundamental Immunology, 2nd ed., W.E. Paul, ed., Raven Press: New York, NY, which is incorporated herein by reference). For treatment of viral infections, the antibodies will typically bind to a protein expressed in cells infected by a particular virus such as the various viral encoded polymerases and HIV-1 Tat, and many other viral proteins well known to those skilled in the art (e.g., see Virology, 2nd ed., B.N. Fields et al., eds., (1990), Raven Press: New York, NY, which is incorporated

herein by reference).

Diagnostic uses of the lipidized antibodies include intracellular staining using labeled, lipidized antibodies which bind to intracellular antigens (e.g., ras) either in fixed histological specimens or in intact, viable cells (e.g., cell cultures or cellular explants).

The invention also provides kits comprising a vial containing a labeled lipidized antibody; such kits can be sold for practicing diagnostic assays on intracellular antigens (as well as being capable of uses of unlipidized antibodies; staining extracellular antigens) according to the methods described. Vials of purified lipidized antibodies can be sold to the clinical lab or scientist as commercial reagents, just like conventional diagnostic products or laboratory biologicals (e.g., restriction enzymes, Taq polymerase, monoclonal antibodies), categories which have sufficient utility to have merited the granting of numerous U.S. patents. Such reagents which can be used in research and diagnostics have been patented; for example, the restriction endonucleases AscI, FseI, PmeI, XcyI, SplI, SrfI, and ApoI, among others, have been patented in the U.S. (see, U.S. Patent Nos. 5,061,628, 5,196,330, 4,588,689, 4,886,756, 5,300,432, 5,200,336, and 5,200,337), among others.

Kits can also be supplied for use with the subject lipidized antibodies in the protection against or detection of a cellular activity or for the presence of a selected cell intracellular protein or the diagnosis of disease. Thus, the subject composition of the present invention may be provided, usually in a lyophilized form in a container, either alone or in conjunction with additional antibodies specific for the desired cell type. The lipidized antibodies, which may be conjugated to a label or toxin, or unconjugated, are included in the kits with buffers, such as Tris, phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g., serum albumin, or the like, and a set of instructions for use. Generally, these materials will be present in less than about

5% wt. based on the amount of active antibody, and usually present in total amount of at least about 0.001% wt. based again on the antibody concentration. Frequently, it will be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient may be present in from about 1 to 99% wt. of the total composition. Where a second antibody capable of binding to the lipidized antibody is employed in an assay, this will usually be present in a separate vial. The second antibody is typically conjugated to a label and formulated in an analogous manner with the antibody formulations described above, as well as typically also being lipidized itself.

The lipidized antibodies of the present invention are also suited for use in improved diagnostic methods and protein purification methods. For example, many intracellular proteins are unstable (e.g., short half-life, susceptible to proteolysis) or prone to aggregation (e.g.,  $\beta$ -amyloid protein) making purification and/or diagnostic detection difficult. Lipidized antibodies are able to penetrate living cells and bind to specific intracellular target antigens; such antibody-antigen binding may stabilize the target antigen and block enzymes involved in degradation of the target antigen (e.g., proteases, ubiquitin-conjugating enzymes, glycosidases) facilitating detection and/or purification of the target antigen.

In one variation of the invention, a lipidized antibody which specifically binds to an intracellular target antigen is contacted with live cells comprising the intracellular target antigen under physiological conditions (e.g., cell culture conditions, somatic conditions) and incubated for a suitable binding period (e.g., from about 10 minutes to several hours). The lipidized antibody specifically binds to the target antigen forming an antigen-antibody complex which is less susceptible to degradation and/or aggregation than the target antigen itself. Typically, the cells are then fixed and permeabilized and the antigen-antibody complex, comprising the target antigen bound

to the lipidized antibody, is detected, usually with a labeled secondary antibody that specifically binds the the lipidized antibody. Examples of preferred labels attached to the secondary antibody are: FITC, rhodamine, horseradish

5 peroxidase conjugates, alkaline phosphatase conjugates,  $\beta$ -galactosidase conjugates, biotinyl moieties, radioisotopes, and the like. In some embodiments, the secondary antibody may be lipidized and the fixation and/or permeabilization steps may be omitted and replaced with substantial washing of the cell  
10 sample to remove non-specific staining. It may also be possible to use a lipidized, labeled primary antibody directly and omit the second antibody. Labelled protein A may also be substituted for a secondary antibody for the detection of the primary (lipidized) antibody.

15 Lipidized antibodies may also be used for intracellular therapy, such as for binding to a predetermined intracellular target antigen and modifying a biochemical property of the target antigen. For example, multi-subunit proteins, such as heteromultimeric proteins (e.g.,  
20 transcription factors, G-proteins) or homodimeric proteins (e.g., polymerized tubulin) may possess a biochemical activity (e.g., GTPase activity) or other activity that requires intermolecular interaction(s) that may be blocked by a lipidized antibody that specifically binds to one or more  
25 subunits and prevents functional interaction of the subunits. For example, a lipidized anti-Fos antibody which binds to a portion of Fos (e.g., leucine zipper) required for binding to Jun to form a transcriptionally active AP-1 transcription factor (Fos/Jun heterodimer) may block formation of functional  
30 AP-1 and inhibit AP-1-mediated gene transcription. Also for example, a lipidized anti-ras antibody may bind to an epitope of ras which is required for its proper signal transduction function (e.g., a GTP/GDP-binding site, a portion of ras that binds an accessory protein such as GAP, or the like),  
35 thereby modifying the activity of intracellular ras in living cells.

The following examples are offered by way of

illustration, not by way of limitation.

## EXPERIMENTAL EXAMPLES

### EXAMPLE 1

#### 5           Preparation of a Lipidized Bovine IgG

Glycyldioctadecylamide was obtained by linking a glycine residue to dioctadecylamine according to the method described by Behr et al. (1989) Proc. Natl. Acad. Sci. (U.S.A.) 86: 6982, which is incorporated herein by reference.

10 Benzyloxycarbonyl-glycyl-p-nitrophenol at 1 equivalent and triethylamine at 1.1 equivalents in  $\text{CH}_2\text{Cl}_2$  are reacted for 5 hours, followed by addition of  $\text{H}_2$ , 10% Pd/C in  $\text{CH}_2\text{Cl}_2/\text{EtOH}$  and reaction for 1 hour.

Two mg of bovine IgG (Sigma) were dissolved in 400  
15  $\mu\text{l}$  of 300 mM  $\text{NaHCO}_3$  in a 1.5 ml Eppendorf vial. Fifty  $\mu\text{l}$  of a freshly prepared  $\text{NaIO}_4$  solution (42 mg/ml in  $\text{H}_2\text{O}$ ) were added and the vial was wrapped in aluminum foil and gently shaken for 90 min. at room temperature. The reaction medium was then loaded on a PD-10 column (Pharmacia) previously equilibrated  
20 with 10 mM  $\text{Na}_2\text{CO}_3$  (fraction 1), and the column was eluted with 500  $\mu\text{l}$  fractions. Fraction number 7 (between 3 ml and 3.5 ml) contained approximately 1.6 mg of bovine IgG as measured using the Bradford protein assay.

A solution of glycyldioctadecylamide in DMSO was  
25 prepared (5 mg of the lipid into 1 ml of DMSO, vigorously vortexed for several minutes). Under those conditions the lipid was not fully dissolved. Fifty  $\mu\text{l}$  of this solution were taken carefully (and did not contain any undissolved lipid) and were added to 350  $\mu\text{l}$  of fraction 7 obtained as described  
30 above, in an Eppendorf vial. The vial was wrapped in aluminum foil, and the mixture was gently shaken for 20 h at room temperature.

One hundred  $\mu\text{l}$  of a solution of  $\text{NaBH}_4$  (10 mg/ml in  $\text{H}_2\text{O}$ ) were then added. After one hour, 40  $\mu\text{l}$  of a solution of  
35 ethanolamine (15  $\mu\text{l}$  in 1 ml  $\text{H}_2\text{O}$ ) were added. After an additional 1 h, the reaction mixture was loaded on a PD-10 column previously equilibrated in 100 mM HEPES buffer, pH 8.5.

The fraction containing the lipidized IgG (between 3 and 3.5 ml) was collected and stored on ice.

#### Labelling with $^{14}\text{C}$ -acetic anhydride

5  $^{14}\text{C}$ -acetic anhydride (500  $\mu\text{Ci}$ , Amersham) in benzene ( $10 \times 10^6$  cpm/ $\mu\text{l}$ ) was used. Two 5  $\mu\text{l}$  aliquots were added to the 500  $\mu\text{l}$  fraction containing the lipidized IgG at 10 min interval in an Eppendorf vial. The reaction was left on ice. A 500  $\mu\text{l}$  solution of native IgG (800  $\mu\text{g}$  in 100 mM HEPES, pH 10 8.5) was treated the same way.

After 30 min. the vials were warmed to 20 to 25°C, the  $^{14}\text{C}$ -labelled IgGs were separated from free  $^{14}\text{C}$ -acetate on a PD-10 column equilibrated with PBS. Radioactivity incorporated was of approximately  $10 \times 10^6$  cpm for 500  $\mu\text{g}$ .

15

#### Organ uptake studies

Male swiss albinos mice (20g) were used. One hundred  $\mu\text{l}$  of  $^{14}\text{C}$ -labeled lipidized IgG or  $^{14}\text{C}$ -labeled control IgG in PBS (approximately 400,000 dpm each) were administered 20 intravenously by tail vein injection. Mice were killed after 30 min or 3 h, their blood collected in EDTA-containing tubes, and their brain (minus cerebellum and brainstem), spleen, one kidney and one liver lobe were dissected. Organs were homogenized in 1 ml 10 mM Tris buffer, pH 7.4, and 500  $\mu\text{l}$  25 aliquots were counted in a Beckman scintillation counter. Protein concentration in these homogenates was determined by the Bradford assay (Coomassie blue). The blood was centrifuged and 20  $\mu\text{l}$  fractions of the plasma were counted. Table I shows the uptake of  $^{14}\text{C}$  in the brain, liver, spleen and 30 kidney, expressed as the ration of radioactivity in 1  $\mu\text{g}$  protein of the organs divided by the radioactivity in 1  $\mu\text{l}$  plasma (data expressed as  $\mu\text{l}/\mu\text{g}$  protein).

TABLE I

35 <u>Organ</u>	<u>30 minutes</u>		<u>3 hours</u>	
	<u>Control</u>	<u>Lipidized</u>	<u>Control</u>	<u>Lipidized</u>

35

Brain	.20 ± .03	.32 ± .08	.94 ± .05	1.75 ± .09
Kidney	1.46 ± .31	9.50 ± 2.19	1.17 ± .04	3.54 ± .22
Liver	1.26 ± .26	4.95 ± .82	.66 ± .04	7.59 ± .27
Spleen	1.08 ± .27	4.54 ± .76	1.13 ± .03	12.0 ± 2.15

5

Control groups of 4 and 6 mice at 30 min and 3 hr, respectively. Groups receiving the lipidized IgG were of 6 mice at both time points. Data are means ± s.e.m.

10

#### EXAMPLE 2

##### Inhibition of HIV-1 Cytotoxicity with Lipidized Anti-Tat Antibody

A monoclonal antibody which specifically binds the Tat protein of HIV-1 was lipidized according to the method described in Example 1, supra, involving periodate oxidation of carbohydrate on the antibody, followed by covalent attachment of glycyldioctadecylamide to yield a carbohydrate-lipidized antibody, which was eluted from the final PD-10 column with PBS.

Sup T1 cells were maintained in 24-well plates (100,000 cells per ml, in 2 ml of modified RPMI 1640 culture medium). Cells were kept in culture with either: (1) no additional treatment (two controls), (2) in the presence of added native anti-Tat antibody (15 µg/ml), or (3) in the presence of the lipidized anti-Tat antibody (11.7 µg/ml) during the first five days of the experiment. At the end of the first day, HIV-1 IIIB was added to one well of control cells and to the cultures containing native anti-Tat antibody-treated cells or lipidized anti-Tat antibody-treated cells. Viable cells were counted daily. The untreated, HIV-infected cells grew up to a density of approximately 500,000 cells per ml, and their number began to decrease after approximately eight days due to the cytotoxic effect of the virus. Uninfected cells grew up to a density of approximately 1,000,000 cells per ml. Treatment of infected cells with the native anti-Tat antibody did not protect the cells from the cytotoxic effect of the virus. In contrast the lipidized

anti-Tat antibody led to an almost complete protection of the cells from the cytopathic effects of the HIV-1 virus. This protection continued for at least about 5 days after the treatment with the lipidized antibody was interrupted. The

5 results are presented in Fig. 3.

In another experiment, Sup T1 cells were maintained in culture as described in the previous example and kept in culture without any treatment and without any infection, infected with HIV-1 IIIB with no treatment, treated with the  
10 native anti-Tat antibody (1  $\mu$ g/ml) and infected, or treated with the lipidized anti-Tat antibody (1  $\mu$ g/ml) and infected. In the last three conditions, the virus was added at the end of the first day in culture. In the last two conditions, the native or lipidized antibody was present from day 1 until day  
15 7.

The data presented in Table II show that, while the native anti-Tat antibody has little if any effect on viable cell number and reverse transcriptase activity, the lipidized antibody induced a significant protection of the cells in  
20 culture from the cytopathic effect of the virus and a significant decrease in reverse transcriptase activity. The latter suggests that the lipidized antibody could inhibit intracellular HIV-1 replication.

TABLE II

Effect of a Lipidized Anti-Tat Antibody on Viable  
Cell Number and Reverse Transcriptase Activity  
in Sup T1 Cells Infected with HIV-1

		Viable Cells ( $\times 10^6$ ) Days in Culture						
		1	2	3	5	6	7	8
5	Conditions							
10	Untreated, Uninfected	1.15	1.28	1.52	1.63	1.69	1.76	1.72
15	Untreated, Infected	1.12	1.2	1.18	1.12	0.92	0.64	0.51
	Treated with native anti-Tat Ab Infected	1.12	1.2	1.21	1.15	0.96	0.67	0.51
20	Treated with lipidized anti-Tat Ab Infected	1.15	1.26	1.3	1.36	1.17	0.99	0.75
25								
		Reverse Transcriptase Activity (cpm/ $10^9$ cells) Days in Culture						
		1	2	3	5	6	7	8
30	Conditions							
	Untreated, Uninfected	2	2	1	2	2	1	1
35	Untreated, Infected	3	2	4	175	264	337	367
	Treated with native anti-Tat Ab Infected	2	2	3	151	237	259	331
40	Treated with lipidized anti-Tab Ab Infected	3	2	2	57	135	179	184

HIV-1-infected SupT1 cells were treated daily with anti-Tat antibody in native or lipidized form or with rsCD4 (all proteins used at 1  $\mu$ g/ml) starting from Day 1 before addition of HIV-1 virus containing supernatants until 10 days post infection. Cell numbers and reverse transcriptase activity (RT) in the culture medium were determined every day starting from Day 2 post-infection. By Day 10, the native anti-Tat still had no significant effect on either cell counts or RT activity, whereas the lipidized anti-Tat antibody

increased cell viability as compared to untreated, infected cells by approximately 70% and decreased RT activity by approximately the same extent. Cultures were continued for 3 days without further addition of antibodies. Effects of the lipidized anti-Tat persisted for the 3 days, indicating that the lipidized anti-Tat antibodies had accumulated in the cells in amounts high enough to provide sustained protection against viral infection/replication. The magnitude of the effects of the lipidized anti-Tat antibody on cell viability and RT activity were very similar to those observed with rsCD4 at the same dose. Increasing the concentration of the lipidized anti-Tat antibodies to 10  $\mu\text{g/ml}$  did not induce further decrease in RT activity.

### Example 3

#### Ability of Lipidized Anti-Tat to Inhibit the Transcriptional Activity of Tat on the HIV-1 LTR

A HeLa cell line stably transfected with a polynucleotide expressing CD4, the membrane receptor mediating HIV-1 infection, and also containing a reporter construct comprising an HIV-1 long terminal repeat (LTR) in operable linkage to and driving transcription of a linked reporter gene (chloramphenicol acetyltransferase; CAT). These cells (HLCD4-CAT) are susceptible to HIV-1 infection which produces functional Tat protein; the binding of newly synthesized Tat to the HIV-1 LTR leads to transcription of the linked CAT gene. Thus, the magnitude of CAT expression is approximately proportional to the extent of HIV-1 infection and the activity of Tat protein in the cells.

Cultured HeLa cells ( $3 \times 10^5$  cells/ml in DMEM with 10% fetal bovine serum) were exposed to the same concentrations (1 or 10  $\mu\text{g/ml}$ ) of various antibodies (in native or lipidized form) or recombinant soluble CD4 (rsCD4) for 1 hour and were extensively washed prior to addition of HIV-containing cell culture supernatants (100  $\mu\text{l}$ ). Twenty-four hours later the cells were harvested and CAT expression was measured by the method of Ho et al. (1984). Each experiment was run in quadruplicate and conducted four different time. Fig. 4 shows that the lipidized anti-Tat antibody significantly inhibited CAT activity (by approximately 75%), whereas native

(unlipidized) anti-Tat antibody, lipidized anti-gp120 antibody, or rsCD4 were far less effective in inhibiting CAT activity. These data indicate that lipidized anti-Tat was able to specifically bind its intracellular target, Tat, and inhibit the target's activity as a transcriptional activator of the LTR/reporter gene construct.

Moreover, the data showing passage of the lipidized anti-Tat antibody into HeLa cells indicates that the transport mechanism does not likely require endosome formation, since HeLa cells are reported to undergo little if any phagocytosis.

#### Example 4

##### Preparation of Lipidized Immunoglobulins Reactive with an Intracellular Protein

Glycyldioctadecylamide is obtained by linking a glycine residue to dioctadecylamine according to the method described by Behr et al. (1989) Proc. Natl. Acad. Sci. (U.S.A.) 86: 6982, which is incorporated herein by reference. Benzyloxycarbonyl-glycyl-p-nitrophenol at 1 equivalent and triethylamine at 1.1 equivalents in  $\text{CH}_2\text{Cl}_2$  are reacted for 5 hours, followed by addition of  $\text{H}_2$ , 10% Pd/C in  $\text{CH}_2\text{Cl}_2/\text{EtOH}$  and reaction for 1 hour.

##### Anti-Human c-Myc Ig

Glycosylated murine immunoglobulins that bind specifically to human c-myc protein are prepared by separately culturing the hybridoma cell lines MYC CT9-B7.3 (ATCC CRL 1725), MYC CT 14-G4.3 (ATCC CRL 1727), and MYC 1-9E10.2 (ATCC CRL 1729) in RPMI 1640 with 10 percent fetal bovine serum under specified conditions (Evan et al. (1985) Mol. Cell. Biol. 5: 3610, incorporated herein by reference) and the monoclonal antibodies secreted are collected and purified by conventional methods known in the art.

About 2 mg of each purified monoclonal antibody are dissolved in 400  $\mu\text{l}$  of 300 mM  $\text{NaHCO}_3$  in a 1.5 ml Eppendorf vial. Fifty  $\mu\text{l}$  of a freshly prepared  $\text{NaIO}_4$  solution (42 mg/ml in  $\text{H}_2\text{O}$ ) is added and the vial is wrapped in aluminum foil and gently shaken for 90 min. at room temperature. The reaction

medium is then loaded on a PD-10 column (Pharmacia) previously equilibrated with 10 mM  $\text{Na}_2\text{CO}_3$  (fraction 1), and the column is eluted with 500  $\mu\text{l}$  fractions. The fraction(s) containing at least approximately 500  $\mu\text{g}$  of IgG as measured using the  
5 Bradford protein assay are collected.

A solution of glycyldioctadecylamide in DMSO is prepared (5 mg of the lipid into 1 ml of DMSO, vigorously vortexed for several minutes). Under those conditions the lipid is not fully dissolved. Fifty  $\mu\text{l}$  of this solution is  
10 taken carefully and added to 350  $\mu\text{l}$  of the purified IgG fractions obtained as described above, in an Eppendorf vial. The vial is wrapped in aluminum foil, and the mixture is gently shaken for 20 h at room temperature.

One hundred  $\mu\text{l}$  of a solution of  $\text{NaBH}_4$  (10 mg/ml in  
15  $\text{H}_2\text{O}$ ) is then added. After one hour, 40  $\mu\text{l}$  of a solution of ethanolamine (15  $\mu\text{l}$  in 1 ml  $\text{H}_2\text{O}$ ) is added. After an additional 1 h, the reaction mixture is loaded on a PD-10 column previously equilibrated in PBS. The fraction containing the lipidized murine anti-human-myc IgG (between 3 and 3.5 ml) is  
20 collected and stored on ice.

#### Anti-HMG CoA Reductase Ig

Glycosylated murine immunoglobulins that bind specifically to the intracellular enzyme HMG CoA reductase are  
25 prepared by separately culturing the hybridoma cell line A9 (ATCC CRL 1811) in DMEM with 4.5 g/l glucose, 5% horse serum and 2.5% fetal bovine serum as described (Goldstein et al. (1983) J. Biol. Chem. 258: 8450, incorporated herein by reference) and the monoclonal antibodies secreted are collected  
30 and purified by conventional methods known in the art.

About 2 mg of each purified monoclonal antibody are dissolved in 400  $\mu\text{l}$  of 300 mM  $\text{NaHCO}_3$  in a 1.5 ml Eppendorf vial. Fifty  $\mu\text{l}$  of a freshly prepared  $\text{NaIO}_4$  solution (42 mg/ml in  $\text{H}_2\text{O}$ ) is added and the vial is wrapped in aluminum foil and  
35 gently shaken for 90 min. at room temperature. The reaction medium is then loaded on a PD-10 column (Pharmacia) previously equilibrated with 10 mM  $\text{Na}_2\text{CO}_3$  (fraction 1), and the column is eluted with 500  $\mu\text{l}$  fractions. The fraction(s) containing at

least approximately 500  $\mu$ g of IgG as measured using the Bradford protein assay are collected.

A solution of glycyldioctadecylamide in DMSO is prepared (5 mg of the lipid into 1 ml of DMSO, vigorously vortexed for several minutes). Under those conditions the lipid is not fully dissolved. Fifty  $\mu$ l of this solution is taken carefully and added to 350  $\mu$ l of the purified IgG fractions obtained as described above, in an Eppendorf vial. The vial is wrapped in aluminum foil, and the mixture is gently shaken for 20 h at room temperature.

One hundred  $\mu$ l of a solution of  $\text{NaBH}_4$  (10 mg/ml in  $\text{H}_2\text{O}$ ) is then added. After one hour, 40  $\mu$ l of a solution of ethanolamine (15  $\mu$ l in 1 ml  $\text{H}_2\text{O}$ ) is added. After an additional 1 h, the reaction mixture is loaded on a PD-10 column previously equilibrated in PBS. The fraction containing the lipidized anti-HMG CoA reductase IgG (between 3 and 3.5 ml) is collected and stored on ice.

#### Example 5

##### Preparation of Lipidized Immunoglobulins Reactive with a Transmembrane Protein

Glycyldioctadecylamide is obtained by linking a glycine residue to dioctadecylamine according to the method described by Behr et al. (1989) Proc. Natl. Acad. Sci. (U.S.A.) 86: 6982, which is incorporated herein by reference. Benzyloxycarbonyl-glycyl-p-nitrophenol at 1 equivalent and triethylamine at 1.1 equivalents in  $\text{CH}_2\text{Cl}_2$  are reacted for 5 hours, followed by addition of  $\text{H}_2$ , 10% Pd/C in  $\text{CH}_2\text{Cl}_2/\text{EtOH}$  and reaction for 1 hour.

#### Anti-Ras Ig

Glycosylated murine immunoglobulins that bind specifically to ras oncogene protein are prepared by separately culturing the hybridoma cell line 142-24E5 (ATCC HB 8679; U.S. Pats. 5,015,571 and 5,030,565, incorporated herein by reference) in DMEM with 4.5 g/l glucose, 2mM L-glutamine, 1mM sodium pyruvate, non-essential amino acids, 1xBME vitamins, 0.1 mM hypoxanthine, 0.032mM thymidine, 0.05 mg/ml gentamicin, and

10% fetal bovine serum, and the hybridoma cell MX (ATCC HB 9158) in Iscove's DMEM with 1% L-glutamine and HT and 10 percent fetal bovine serum under specified conditions (U.S. Patent 4,820, 631, incorporated herein by reference) and the  
5 monoclonal antibodies secreted from the hybridoma lines are collected and purified by conventional methods known in the art.

About 2 mg of each purified monoclonal antibody are dissolved in 400  $\mu$ l of 300 mM  $\text{NaHCO}_3$  in a 1.5 ml Eppendorf  
10 vial. Fifty  $\mu$ l of a freshly prepared  $\text{NaIO}_4$  solution (42 mg/ml in  $\text{H}_2\text{O}$ ) is added and the vial is wrapped in aluminum foil and gently shaken for 90 min. at room temperature. The reaction medium is then loaded on a PD-10 column (Pharmacia) previously equilibrated with 10 mM  $\text{Na}_2\text{CO}_3$  (fraction 1), and the column is  
15 eluted with 500  $\mu$ l fractions. The fraction(s) containing at least approximately 500  $\mu$ g of IgG as measured using the Bradford protein assay are collected.

A solution of glycyldioctadecylamide in DMSO is prepared (5 mg of the lipid into 1 ml of DMSO, vigorously  
20 vortexed for several minutes). Under those conditions the lipid is not fully dissolved. Fifty  $\mu$ l of this solution is taken carefully and added to 350  $\mu$ l of the purified IgG fractions obtained as described above, in an Eppendorf vial. The vial is wrapped in aluminum foil, and the mixture is gently  
25 shaken for 20 h at room temperature.

One hundred  $\mu$ l of a solution of  $\text{NaBH}_4$  (10 mg/ml in  $\text{H}_2\text{O}$ ) is then added. After one hour, 40  $\mu$ l of a solution of ethanolamine (15  $\mu$ l in 1 ml  $\text{H}_2\text{O}$ ) is added. After an additional 1 h, the reaction mixture is loaded on a PD-10 column  
30 previously equilibrated in PBS. The fraction containing the lipidized murine anti-ras IgG (between 3 and 3.5 ml) is collected and stored on ice.

Hybridoma cell lines referred to in the above examples may be obtained from American Type Culture Collection,  
35 Rockville, MD (ATCC Cell Lines and Hybridomas (1992) 7th Ed, which is incorporated herein by reference).

#### Example 6

Lipidization of a Transmembrane Enzyme

The enzyme gamma-glutamyltranspeptidase (GGT: EC 2.3.2.2) is a widely distributed enzyme that catalyzes the degradation of glutathione and other  $\gamma$ -glutamyl compounds by hydrolysis of the  $\gamma$ -glutamyl moiety or by its transfer to a suitable acceptor. GGT is a heterodimeric glycoprotein, which is synthesized as a precursor protein that is glycosylated and cleaved into the two subunits of the mature enzyme. GGT is anchored to the cell membrane through the N-terminal portion of its heavy subunit. The active site of the enzyme lies on the extracellular portion of the molecule, which is heavily glycosylated.

GGT is separately purified from rat kidney and a cultured human hepatoma cell line according to procedures described previously in the art (Barouki et al. (1984) J. Biol. Chem. 259: 7970; Curthoys and Hughey (1979) Enzyme 24: 383; Matsuda et al. (1983) J. Biochem. 93: 1427; Taniguchi et al. (1985) J. Natl. Cancer Inst. 75: 841; Tate and Meister (1985) Methods Enzymol. 113: 400; and Toya et al. (1983) Ann. N.Y. Acad. Sci. 417: 86, which are incorporated herein by reference).

About 1 mg of each of the purified rat and human GGT preparations are dissolved in 400  $\mu$ l of 300 mM  $\text{NaHCO}_3$  in a 1.5 ml Eppendorf vial. Fifty  $\mu$ l of a freshly prepared  $\text{NaIO}_4$  solution (42 mg/ml in  $\text{H}_2\text{O}$ ) is added and the vial is wrapped in aluminum foil and gently shaken for 60 min. at room temperature. The reaction medium is then loaded on a PD-10 column (Pharmacia) previously equilibrated with 10 mM  $\text{Na}_2\text{CO}_3$  (fraction 1), and the column is eluted with 500  $\mu$ l fractions. The fraction(s) containing at least approximately 100  $\mu$ g of GGT as measured using the Bradford protein assay are collected.

A solution of glycyldioctadecylamide in DMSO is prepared (5 mg of the lipid into 1 ml of DMSO, vigorously vortexed for several minutes). Under those conditions the lipid is not fully dissolved. Fifty  $\mu$ l of this solution is taken carefully and added to 350  $\mu$ l of the purified GGT fractions obtained as described above, in an Eppendorf vial. The vial is wrapped in aluminum foil, and the mixture is gently

shaken for 20 h at room temperature.

One hundred  $\mu$ l of a solution of  $\text{NaBH}_4$  (10 mg/ml in  $\text{H}_2\text{O}$ ) is then added. After one hour, 40  $\mu$ l of a solution of ethanolamine (15  $\mu$ l in 1 ml  $\text{H}_2\text{O}$ ) is added. After an additional  
5 1 h, the reaction mixture is loaded on a PD-10 column previously equilibrated in PBS. The fraction containing the lipidized human and rat GGT (between 3 and 3.5 ml) is collected and stored on ice.

The lipidized human and rat GGT fractions are assayed  
10 for  $\gamma$ -glutamyltranspeptidase activity by conventional assay procedures (Tate and Meister (1983) op.cit., incorporated herein by reference) and the specific activity of the lipidized human GGT and lipidized rat GGT is determined.

The lipidized human and rat GGT is radiolabeled by  
15 iodination with  $^{125}\text{I}$  using chloramine T and approximately 50  $\mu$ g of the radioiodinated lipidized GGT is administered to rats by intraperitoneal injection. After 24 hours, the rats are sacrificed and tissue samples removed for autoradiography to determine the pattern of localization of the lipidized GGT in  
20 the various organs.

#### Example 7

##### Lipidization of an Anti-Actin Antibody and Intracellular Immunostaining

25 In order to demonstrate that lipidized antibodies can localize intracellularly in living cells and bind intracellular targets, an anti-actin antibody was lipidized and evaluated for its ability to penetrate cultured Swiss 3T3 fibroblasts and bind to the cytoskeletal protein actin. Native anti-actin  
30 antibody (unlipidized) was used as a control.

Protein A-purified rabbit anti-actin polyclonal antibodies were lipidized according to the following procedure. A lipoamine, glycyldioctadecylamide, was covalently linked to the carbohydrate moieties of the anti-actin antibodies by  
35 periodate oxidation-sodium borohydride reduction. Antibodies were dissolved in 0.8 ml of 300 mM  $\text{NaHCO}_3$  at a concentration of approximately 0.2 to 1.0 mg/ml. Fifty  $\mu$ l of a freshly prepared aqueous solution of  $\text{NaIO}_4$  (42 mg/ml) were added and the

incubation vials were wrapped in aluminum foil and gently shaken for 90 minutes at room temperature. The reaction mixture was then purified on a PD-10 column (Pharmacia, Piscataway, NJ) equilibrated in and eluted with 10 mM  $\text{Na}_2\text{CO}_3$ .  
5 Fifty  $\mu\text{l}$  of a 10 mg/ml solution of glycyldioctadecylamide in benzene are added to the fraction containing the antibodies (e.g., as determined by  $A_{280}$  monitoring, Bradford assay) and the resulting reaction was incubated for 20 hours at room temperature with gentle shaking. One hundred  $\mu\text{l}$  of a freshly  
10 prepared aqueous solution of  $\text{NaBH}_4$  (10 mg/ml) was then added and incubated at room temperature for one hour, followed by addition of 50  $\mu\text{l}$  of ethanolamine solution (15  $\mu\text{l}$  ethanolamine dissolved in 1 ml of  $\text{H}_2\text{O}$ ). After an additional hour at room temperature, the resultant lipidized antibodies were purified  
15 by chromatography on a PD-10 column equilibrated with phosphate-buffered saline.

#### ELISA Assays

Lipidized anti-actin and lipidized anti-Tat (supra) were evaluated for their binding affinity for specific antigen  
20 relative to native (unlipidized) anti-actin or anti-Tat antibody by ELISA assay. Lipidization of either the anti-actin antibody or the anti-Tat antibody did not produce a measurable loss of affinity of the antibodies for their respective antigens as compared to their native (unlipidized) antibody.

#### Intracellular Immunostaining

To demonstrate that lipidized anti-actin antibodies are able to bind intracellular actin in live cells, lipidized anti-actin antibody or native anti-actin antibody were contacted with cultured Swiss 3T3 cells for 1 hour, followed by  
30 extensive washing to remove residual anti-actin antibodies. The cells were subsequently fixed and permeabilized and the anti-actin antibodies were detected with a fluorescent-labeled secondary antibody. While no specific staining could be detected in cells preincubated with the native (unlipidized)  
35 anti-actin antibody, specific actin staining (e.g., stained actin cables) was clearly evident in cells preincubated with the lipidized anti-actin antibodies. The staining pattern observed with the lipidized anti-actin antibody applied prior

to fixation was similar to that seen using native (unlipidized) anti-actin antibody incubated with the cells following fixation and permeabilization. These data demonstrate that the lipidized anti-actin antibodies were able to reach and bind intracellular actin, and that they could still be recognized and bound by the labeled secondary antibodies, indicating that they were functional and substantially intact.

#### Example 8

#### 10 Lipidized anti-Tat antibody enters living cells and blocks HIV-1 viral replication

We have developed a chemical modification of antibodies, lipidation, which enables their intracellular delivery into living cells. Intracellular localization of lipidated antibodies was demonstrated by confocal microscopy and by measuring cellular uptake of 125-I-labeled lipidated antibodies. Functionally, a lipidated monoclonal antibody directed against the Tat protein from HIV-1 inhibited viral replication as shown by increased viability of infected cells and, concomitantly, decreased reverse transcriptase activity. The antibody in its native form had no such effect. These data show that lipidated antibodies can reach, selectively bind and functionally inhibit intracellular targets. Lipidation may help to facilitate the development of intracellular immunotherapy for AIDS.

The HIV-1 regulatory protein Tat is essential for viral replication functioning as a transactivator of the viral promoter when bound to the TAR sequence of nascent transcripts. Thus, antibodies against Tat could conceivably inhibit viral replication provided they could be efficiently delivered inside infected cells. However, the use of antibodies to target intracellular proteins has been restricted by the need for prior membrane permeabilization, direct micro-injection, or by transduction of single chain antibody expression vectors. As a less invasive approach to antibody delivery into living cells, we have linked a lipoamine, glycyldioctadecylamide to the carbohydrate moieties of antibodies by periodate chemistry. In

this study, we have applied lipidation technology to monoclonal antibodies against the Tat protein. The intracellular delivery of lipidated anti-Tat antibodies (L-anti-Tat) was first established by using confocal microscopy to visualize the presence of these antibodies inside living cells. SupT1 cells, a CD4+lymphocytic cell line, were infected with HIV-1<sub>IIIB</sub>, then exposed to fluorescently labeled L-anti-Tat (1µg/ml). After a 1 hr incubation period excess antibody was washed out, and cells were examined by confocal fluorescence microscopy. Successive images were taken at various depths through cells, from 1 µm to 6 µm.

Fluorescence was observed intracellularly, apparently distributed throughout the cell with no obvious localization in any organelle or at the plasma membrane. This was most clearly illustrated at the medial cross section of the cell.

The staining pattern with L-anti-Tat contrast sharply with that observed in HIV infected cells incubated with fluorescently labeled native anti-Tat antibody which showed a ring-shaped staining pattern suggestive of accumulation at the cell surface with no intracellular delivery.

The L-anti-Tat antibody was clearly present intracellularly but with substantially lower fluorescence intensity than in infected cells. A similarly low level of fluorescence intensity was observed when HIV-infected cells were stained with fluorescently labeled lipidated mouse IgG<sub>1</sub>. Thus, the difference in fluorescence intensity between infected and uninfected SupT1 cells with L-anti-Tat was not due to nonspecific membrane damage induced by the virus, because it was not observed with L-IgG. Instead, the enhanced intensity in infected cells suggests intracellular trapping of antigen-bound L-anti-Tat.

Intracellular delivery of lipidated antibodies was further established by quantitating the uptake of <sup>125</sup>I-L-anti-Tat in infected and uninfected cells (Table III). While uptake of <sup>125</sup>I-n-anti-Tat was very low (<0.5% of added antibody) and did not depend on whether cells were infected, uptake of L-anti-Tat was greatly increased, to 4.8% and 32.8% in uninfected and infected cells, respectively. Uptake of a lipidated

control antibody (L-IgG), while markedly higher than that of n-anti-Tat, was the same (approximately 4% of added antibody) independent of HIV1 infection. These experiments demonstrate efficient uptake of L-antibodies and consistent with the confocal microscopy data, suggest intracellular trapping of antigen-bound L-anti-Tat.

Table III Update of  $^{125}\text{I}$ -antibodies in uninfected and infected SupT1 cells.

Cells	L-anti-Tat	L-anti-IgG	N-anti-Tat
Infected	45,704 $\pm$ 1749 (32.8%)	4035 $\pm$ 521 (3.7%)	345 $\pm$ 85 (0.47%)
Uninfected	3124 $\pm$ 562 (4.8%)	3642 $\pm$ 385 (4.1%)	391 $\pm$ 47 (0.38%)

SupT1 cells ( $30 \times 10^6$  cells in 0.5 ml) were incubated with  $^{125}\text{I}$ -L-anti-Tat antibody for 2 hrs at 37°C. Antibodies were radiolabeled using Iodobeads (Pierce). One hundred fifty thousand cpms (representing 3.3ug, 4.1ug and 2.9ug of L-anti-Tat, L-anti-IgG and n-anti-Tat respectively) were added to the cells. After incubation the cells were treated with 10mM trypsin for 20 min at 37°C to remove extracellular antibody. (Complete removal of membrane associated protein by this procedure was confirmed previously by FACS analysis of cells labeled with FITC-anti-CD4 and FITC-anti-CD8 antibodies (data not shown)). The Table indicates the total amount of cell-associated, trypsin-insensitive radioactivity obtained under each condition. The values presented are the means  $\pm$  sd from three experiments.

We next tested the hypothesis that L-anti-Tat could interfere with intracellular Tat function. This was first tested using a HeLa cell line, HLCD4-CAT, which had been transfected to stably express CD4 antigen, the membrane receptor mediating HIV-1 infection, and the reporter gene chloramphenicol acyltransferase (CAT) under the control of the HIV-1 promoter. These cells are susceptible to HIV-1 infection which results in intracellular synthesis of Tat protein, inducing CAT expression. The magnitude of CAT expression is

proportional to the extent of HIV-1 infection.

HLCD4-CAT cells were exposed for 1hr to either L-anti-Tat, n-anti-Tat, L-anti-gp120, or recombinant soluble CD4 (rsCD4). The cells were washed extensively prior to addition of HIV-1 virus-containing supernatant. Twenty-four hours later the cells were harvested and CAT expression measured. Neither n-anti-Tat, L-anti-gp120, nor rsCD4 had any significant effect. In contrast, L-anti-Tat induced a reduction in CAT expression of approximately 75% (Fig. 5). Lack of an effect by the L-anti-gp120 suggests that L-anti-Tat-induced inhibition was due to a specific interaction of the antibody with Tat. These results indicate that L-anti-Tat was able to enter into the HeLa cells, bind Tat protein, and interfere with its functions.

We finally investigated whether L-anti-Tat could block active HIV-1 replication in living cells. One set of experiments utilized SupT1 cells infected with HIV-1<sub>IIIB</sub> (Fig. 6A and 6B). Figure 6A shows that treatment with L-anti-Tat (1  $\mu$ g/ml) preserved cell viability to approximately 90% that of infected cells. Concomitantly, RT activity in the L-anti-Tat treated cultures was decreased by 75% (Fig. 6B). A higher concentration of L-anti-Tat (20  $\mu$ g/ml) did not induce any further decrease in RT activity (data not shown). The magnitude of the effects of the L-anti-Tat on cell viability and RT activity were similar to those observed with rsCD4 in this system. The n-anti-Tat had no significant effect on cell viability or RT activity. In other experiments, p24 protein, quantitated by ELISA (detection limit 50 pg/ml) was employed as an indicator of HIV-1 replication. L-Anti-Tat decreased p24 levels in the SupT1 cultures, by day 9, to 29 ng/ml. compared to 163 and 147 ng/ml for untreated and n-anti-Tat treated cells, respectively. Several other anti-HIV antibodies were also lipidated and their ability to block HIV-1 replication was studied (data not shown). These antibodies, anti-integrase, anti-Rev, an anti-p17 (1  $\mu$ g/ml) had no inhibitory effect. The lack of effect of these antibodies suggests that protection by the L-anti-Tat was due to a specific interaction with the Tat protein.

To assess the effect of L-anti-Tat on the

reactivation of latent HIV-1 infection, two cell lines latently infected with HIV-1, J1.1 a lymphocytic cell line and OM-1-.1 a monocytic cell line were used. Viral replication was induced with TNF-alpha and antibodies were administered simultaneously with the cytokine. After 72 hr. HIV-1 infection was quantitated by ELISA assay for p24. As shown in Fig. 7, cells treated with L-anti-Tat (1  $\mu$ M) had p24 levels in the 10 ng/ml range. By comparison, those treated with n-anti-Tat, or untreated controls, exhibited p24 levels in the 100 ng/ml range.

Previous studies in which cells genetically engineered to express single-chain antibodies against gp120 or Rev exhibited lower HIV-1 infectivity, elegantly illustrated the concept that intracellular antibodies could neutralize viral proteins. Our data show that antibody lipidation, a simpler and more widely applicable technology, enables their entry into living cells in quantities sufficient to interfere with specific intracellular protein function.

#### Materials and Methods

SupT1 cells were cultured either under control conditions or with cell supernatant from H9 cells infected with HIV-1<sub>IIIB</sub> (10 TCID<sub>50</sub>). (HIV-1<sub>IIIB</sub> (HTLV-IIIB/H9) isolate was obtained from the NIH AIDS Research and Reference Reagent Program. The virus was expanded in HUT78 cells and used in culture at a 10 TCID<sub>50</sub> concentration.) One ug/ml of L-anti-Tat or n-anti-Tat was added to the cultures for 1hr at which time the cells were washed and applied to glass slides.

Recombinant Tat, generated in a baculovirus expression system, was used to prepare a mouse anti-Tat monoclonal antibody, by AGMED, Inc., Bedford, MA. This antibody (subclass IgG1) was purified by protein A Sepharose chromatography. Control antibody (mouse monoclonal IgG1 was from Sigma Immunochemicals (St. Louis, MO). Other anti-HIV-1 antibodies used in this study were polyclonal antibodies generated in either rabbit or sheep and were obtained from the NIH AIDS Research and Reference Reagent Program.

The lipoamine, glycyldioctadecylamide, was covalently

linked to the carbohydrate moieties of antibodies by periodate oxidation-sodium borohydride reduction. Glycyldioctadecylamide was prepared from glycine and dioctadecylamine essentially as described. Antibodies were dissolved in 300 mM  $\text{NaHCO}_3$  at a typical concentration of 1 to 5 mg/ml.  $\text{NaIO}_4$  as a freshly prepared aqueous stock solution (80 mg/ml), was added to a final concentration of 8 mg/ml and the incubation vials were wrapped in aluminum foil and mixed on a rotator for 90 in at room temperature. The oxidized antibodies were purified on Econopac 10DG desalting columns (BioRad) equilibrated in, and eluted with 10 mM  $\text{Na}_2\text{CO}_3$ . A 10 mg/ml solution of glycyldioctadecylamide in DMSO was added to yield a final lipoamine concentration of 1.3 mg/ml and the mixture was incubated for 20 hr at room temperature on the rotator.  $\text{NaBH}_4$ , as a freshly prepared aqueous stock solution (10 mg/ml) was then added to final concentration of 1.8 mg/ml, followed after 1 hr by 50  $\mu\text{l}$  of ethanolamine (15  $\mu\text{l}$  in 1 ml  $\text{H}_2\text{O}$ ). After an additional 1 hr. the lipidated antibodies were purified by chromatography on Econopac 10DG columns equilibrated with 50 mM sodium phosphate, 0.9%  $\text{NaCl}$ . pH 7.4. Lipidated antibody solutions were then filtered through a 0.2  $\mu$  syringe filter (Millex GV, Millipore Corp.)

To estimate the number of lipid moieties linked to each antibody molecule, the anti-Tat antibody was chemically modified as described above, with a starting protein concentration of 5 mg/ml, except that  $^{14}\text{C}$ -glycyldioctadecylamide (obtained from Dalton Chemical Laboratories, Inc., Toronto, Canada) was added to the unlabeled lipamine as a tracer. The number of lipamine residues linked to the antibody was determined by measuring the radioactivity incorporated in the antibody by liquid scintillation counting, and the amount of antibody, determined by a Lowry assay. By this procedure, the average number of lipoamine moieties per antibody molecule was estimated to be about 8.

By attaching the lipid molecules to the carbohydrate residues on the antibody, distant from the hypervariable binding domain, epitope specificity and binding efficiency should not be affected. This was confirmed by ELISA,

demonstrating that lipidation did not affect the ability of the anti-Tat antibody to bind recombinant Tat protein (not shown).

HLCD4-CAT cells were obtained from the NIH AIDS Research and Reference Reagent Program and were contributed by Drs. Felber and Pavlakis. The cells were plated at a density of  $3 \times 10^5$  cells/ml in 24 well culture plates containing DMEM with 10% fetal bovine serum. Cells were treated with either 10 or 20  $\mu\text{g/ml}$  of L-anti-Tat, or 10  $\mu\text{g/ml}$  L-anti-HIV-1 gp120 antibody, 10  $\mu\text{g/ml}$  n-anti-Tat antibody, or 10  $\mu\text{g/ml}$  rsCD4 (AGMED). After 1 hr. the cells were extensively washed, and 100  $\mu\text{l}$  of HIV-1<sub>IIIB</sub>-containing (HIV-1<sub>IIIB</sub>, 10 TCID<sub>50</sub>) supernatant were added. After 24 hr the cultures were harvested and CAT activity was measured using the method described by Seed et al. CAT activity was measured by cutting appropriate spots as identified from an autoradiogram and scintillation counting of incorporated  $^{14}\text{C}$ . Incorporated radioactivity from uninfected cells, and HIV-1-infected cells either untreated or treated with L-anti-Tat antibody at 10 or 20  $\mu\text{g/ml}$  or L-anti-gp120 antibody at 10  $\mu\text{g/ml}$  was determined.

Figure 6A & 6B Effect of L-anti-Tat antibody on HIV-1 replication in living cells.

Fig. 6A & 6B. HIV-1<sub>IIIB</sub>-infected SupT1 cells were  
5 cultured in the presence of 1  $\mu$ g/ml of either native or L-anti-Tat antibody, L-anti-gp120 antibody, or rsCD4, in 2 ml of RPMI 1640 medium supplemented with 10% fetal bovine serum, per well. The proteins were added 24 h prior to the addition of HIV-1 virus-containing supernatants (10 TCID<sub>50</sub>). Three hundred  $\mu$ l  
10 aliquots were taken daily from day 2 through day 13 for measurements of cell number (100  $\mu$ l) (6A) and RT activity (200  $\mu$ l) (6B), and 300  $\mu$ l of fresh medium containing the appropriate protein was added to each well until day 10 (arrow). On subsequent days, the fresh medium added did not contain any  
15 antibody or rsCD4. RT activity was measured by the method of Ho et al. and is expressed as cpm/10<sup>5</sup> cells. The data are means  $\pm$  S.D. from four separate experiments.

Fig. 7. Latently infected cell lines J1.1 and OM-  
20 10.1 were obtained from the NIH AIDS Research and Reference Reagent Program and were contributed by Drs. Folks and Butera. These cells were cultured at 1 x 10<sup>6</sup> cells/ml in RPMI 1640 supplemented with 10% FBS. They were stimulated with TNF $\alpha$  (10U and 100U for J1.1 and OM-10.1 cells, respectively) for 72 hrs  
25 in the presence of L-anti-Tat or n-anti-Tat antibody (1  $\mu$ g/ml for each). On hundred  $\mu$ l aliquots from the supernatants were harvested and assayed for p24 by ELISA (detection limit 50 pg/ml).

30 The foregoing description of the preferred embodiments of the present invention has been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise form disclosed, and many modifications and variations  
35 are possible in light of the above teaching.

Such modifications and variations which may be apparent to a person skilled in the art are intended to be within the scope of this invention.

CLAIMS

1. A method for modifying the characteristics of a protein, comprising the steps of:

attaching a lipid substituent to the protein by a covalent linkage of at least one lipoamine residue to a carbohydrate side chain to produce a lipidized protein; and recovering the lipidized protein.

2. A method according to Claim 1, wherein the lipid substituent is a lipoamine.


3. A method according to Claim 2, wherein the step of attaching further comprises the steps of oxidizing a carbohydrate on a glycosylated polypeptide to produce an oxidized glycoprotein; and reacting the oxidized glycoprotein with a lipoamine under suitable reaction conditions to form a lipidized protein.

4. A method according to Claim 2, wherein the lipoamine is a straight-chain lipoamine according to the formula:



where R is selected from the group consisting of: disubstituted alkyl (alkylene); 1,4-disubstituted cyclohexyl; disubstituted aryl (arylene); amido group of the formula - (CHR<sub>1</sub>)-CO-NH- wherein R<sub>1</sub> is hydrogen or an amino group; alkylcarbonyl; and phosphate diester; n is 1-50.

5. A method according to Claim 2, wherein the lipoamine is a branched-chain lipoamine according to the formula:



where R' is: a trisubstituted alkyl; a trisubstituted aryl; an amido group of the formula -(CHR<sub>1</sub>)-CO-N< wherein R<sub>1</sub> is

13 hydrogen or an amino group; an imino group of the formula -  
14  $\text{CHR}_2\text{-NH-CH<}$  wherein  $\text{R}_2$  is hydrogen or an amino group or an  
15 imino group of the formula  $\text{-CH}_2\text{-N<}$ ; or a phosphate diester; m  
16 is 1-50; n is 1-50; and m and n are selected independently.

1 6. A method according to claim 5, wherein the branched-chain  
2 lipoamine is glycyldioctadecylamide.

1 7. A method according to Claim 1, wherein the protein is a  
2 naturally-occurring glycoprotein.

1 8. A method according to Claim 1, wherein the protein is  
2 encoded by an immunoglobulin superfamily gene.

1 9. A method for targeting an intracellular protein for  
2 binding with an antibody in a cell, comprising contacting the  
3 cell with a lipidized antibody which binds specifically with  
4 the intracellular protein.

1 10. A method according to Claim 9, wherein the lipidized  
2 antibody comprises at least one lipoamine residue linked to a  
3 carbohydrate side chain of an immunoglobulin.

1 11. A method according to Claim 14, wherein the lipoamine is  
2 glycyldioctadecylamide.

1 12. A method according to Claim 13, wherein the lipidized  
2 antibody is administered to a living mammalian cells in vivo.

1 13. A method according to Claim 12, wherein the lipidized  
2 antibody is taken up into the living cells to a greater extent  
3 than is a comparable antibody having the same amino acid  
4 sequence(s) and the same glycosylation pattern and lacking  
5 lipidization.

1 14. A composition for therapy or prophylaxis of a disease,  
2 comprising a therapeutically effective dosage of a lipidized  
3 protein.

1 15. A composition according to Claim 14, wherein the lipidized  
2 protein is an antibody.

1 16. A composition according to Claim 15, wherein the antibody  
2 binds to an intracellular protein.

1 17. A composition according to Claim 16, wherein the  
2 intracellular protein is a viral-encoded protein.

1 18. A composition according to Claim 17, wherein the viral-  
2 encoded protein is a Tat protein encoded by HIV-1.


1 19. A composition for prophylaxis, comprising a  
2 prophylactically effective dosage of a lipidized antibody  
3 wherein a lipid substituent is covalently linked to the  
4 antibody by a covalent linkage of at least one lipoamine  
5 residue to a carbohydrate side chain to produce a lipidized  
6 antibody.

1 20. A composition comprising a lipidized antibody linked to a  
2 diagnostic reporter, wherein a lipid substituent is covalently  
3 linked to the antibody by a covalent linkage of at least one  
4 lipoamine residue to a carbohydrate side chain to produce a  
5 lipidized antibody.

1 21. A composition of claim 20, wherein the antibody binds to  
2 an antigen intracellularly in living cells.



1 22. A composition of claim 22, wherein the antibody binds to  
2 the HIV-1 Tat protein intracellularly in HIV-infected human  
3 cells.

1 23. A method for diagnosing a pathological condition,  
2 comprising the steps of:  
3           administering a lipidized antibody comprising a  
4 diagnostic reporter to a cell sample; and  
5           detecting the presence of cells in which the  
6 diagnostic reporter is preferentially localized.



**FIG. 1.**  
**SUBSTITUTE SHEET (RULE 26)**

2/7

**FIG. 2.**

3/7




FIG. 3A.






FIG. 3B.

**FIG. 4.****FIG. 5.**

SUBSTITUTE SHEET (RULE 26)

5/7




FIG. 6A.

6/7





FIG. 6B.

7/7

**FIG. 7.**

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09788**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/178.1, 179.1, 181.1, 182.1, 183.1; 435/7.1, 972; 436/536; 530/391.1, 391.3, 391.5, 391.7, 391.9, 402

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Extra Sheet.**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KABANOV et al. Effective inhibition of viral reproduction by hydrophobised antiviral antibodies. Biomedical Science. January 1990, Vol. 1, No. 1, pages 63-67, see entire document.	1-23
Y	KABANOV et al. Fatty acylation of proteins for translocation across cell membranes. Biomedical Science. January 1990, Vol. 1, No. 1, pages 33-36, see entire document.	1-23
Y	WO 90/10448 A2 (GENENTECH, INC.) 20 September 1990, see entire document.	1-23

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 25 JULY 1996	Date of mailing of the international search report 04 OCT 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer RON SCHWADRON Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/09788

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	RODWELL et al. Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations. Proceedings National Academy Science USA. April 1986, Vol. 83, pages 2632-2636, see entire document.	1-23

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US96/09788

**A. CLASSIFICATION OF SUBJECT MATTER:**

IPC (6):

A61K 39/395, 39/40, 39/42, 39/44; G01N 33/53, 33/531, 33/532, 33/536, C07K 16/00, 16/46, 19/00; C12P 21/08

**A. CLASSIFICATION OF SUBJECT MATTER:**

US CL :

424/178.1, 179.1, 181.1, 182.1, 183.1; 435/7.1, 972; 436/536; 530/391.1, 391.3, 391.5, 391.7, 391.9, 402

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

MEDLINE, BIOSIS, EMBASE, DERWENT WPI, CHEM AB, APS search terms: author names, lipidized, lipid, antibody, immunoglobulin, conjugate, immunoconjugate, lipoamine, oxidized, oxidizing, glycoprotein, protein, fatty acid